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Abstract 
Approximately one in a hundred people suffer from schizophrenia. Symptoms are partially 
improved by medication but most symptoms are lifelong. There is no cure. The causes and 
mechanisms are still unknown. Glutamate, an excitatory neurotransmitter, is a possible cause 
of the schizophrenia symptoms. Excessive glutamate levels eventually lead to the 
neurodegeneration. Longitudinal studies are necessary to observe the neurodegenerative 
process.  
Seventeen first episode schizophrenia patients and 17 comparable healthy volunteers 
underwent a longitudinal study using proton magnetic resonance imaging and spectroscopy 
to measure structural and neurochemical changes in vivo. Metabolite levels were measured 
from a 1.5cm3 voxel in the left anterior cingulate and the left thalamus using the stimulated 
echo acquisition mode sequence (STEAM). Gray matter in the entire brain was examined 
with a voxel-based morphometry using the Statistical Parametric Mapping. 
Total glutamatergic metabolite levels (tGL), N-acetylaspartate (NAA) levels, and gray matter 
were significantly decreased in schizophrenia over 80 months. Reduced tGL and NAA levels 
were significantly correlated with gray matter loss in areas related to schizophrenic 
symptoms. Loss of tGL levels was negatively correlated with social functioning measure. 
Significantly decreased tGL levels were possibly associated with gray matter loss in the 
voxel of interest. The metabolite signal-to-noise ratio decreased as a function of MR system 
age, but that did not significantly affect the findings presented in this thesis.  
These findings demonstrate the feasibility of long-term MRS studies of neurological 
disorders and have a number of implications for the understanding of the pathophysiology of 
schizophrenia. Changes in glutamatergic metabolites and gray matter losses were consistent 
with neurodegeneration. The effects of an early neurodevelopmental lesion leading to 
glutamatergic abnormalities at the onset of illness or the effects of chronic medication could 
not be ruled out.   
Structural and metabolite changes in these patients over the early years of illness have 
implicated glutamate as a possible target of therapeutic intervention in this disorder. Current 
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treatments do not prevent deterioration of their social skills. The association between the loss 
of glutamatergic metabolites and social functioning in this study suggests that it might be 
possible to arrest this process with pharmaceuticals that target glutamate.  
 
Keywords 
glutamate, glutamine, excitotoxicity, N-acetylaspartate, social functioning, 
neurodegeneration, signal-to-noise ratio, longitudinal study 
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Chapter 1  
1 Introduction 
1.1 Schizophrenia 
Schizophrenia is a severe mental disorder, which was first referred to as dementia 
praecox by Emil Kraepelin in 1896.1 He noticed that some psychotic patients had a 
deteriorating course similar to patients with dementia while the others recovered. The 
latter group was referred to as manic depressive patients. Later, Eugen Bleuler introduced 
the term schizophrenia,2 highlighting the disturbed “sense of self” noticeably present in 
the disorder. Major symptoms of schizophrenia described in the DSM IV criteria3 are 
classified as positive symptoms (e.g. hallucination and delusions), negative symptoms 
(e.g. social withdrawal and flat emotion) and cognitive symptoms (e.g. poor attention and 
executive functioning). Positive symptoms are usually suppressed with the antipsychotic 
drugs while negative symptoms are not improved as much with these medications. Thus 
far, there is no cure for schizophrenia and its causative mechanism is unclear.  
There have been many epidemiological and genetic studies of schizophrenic patients. 
Research has shown that a family member of schizophrenic patients is more likely to 
develop the disease than the general population. In the case of monozygotic twins, the 
chance of developing schizophrenia increases to 50 percent when the other suffers from 
schizophrenia.4 If someone is a first degree relative, the risk is about 10 percent compared 
to about 1 percent in the general population. A few groups reported that the number of 
schizophrenia patients born during a flu epidemic in 1957 was significantly higher than 
the general population.5 Other studies have found increased risk of schizophrenia 
associated with obstetrical complications6 such as bleeding in pregnancy. Thus, 
schizophrenia is a complex disorder with both genetic and environmental factors 
contributing. 
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1.1.1 Pathological evidence 
From post mortem studies, abnormalities in nerve cells in schizophrenia were found such 
as pyramidal cell disarray in the hippocampus, associated with long-term memory.7 
Pakkernberg8 found decreased total neuronal number in the mediodorsal thalamus, a 
central sensory processing region in the human brain. Selemon et al.9 showed higher 
neuronal density in the prefrontal cortex in schizophrenia compared to the normal human 
brain, suggesting a potential malfunction in higher order processing. In other studies, 
significantly decreased GABAergic interneurons were seen in schizophrenia.10 GABA 
(gamma aminobutryric acid) is an inhibitory neurotransmitter, which mediates the 
glutamatergic signals in the brain.11,12 Significantly decreased glutamic acid 
decarboxylase (GAD)67 expression was seen in the brain tissues of schizophrenia 
subjects. GAD67 protein is produced when GABA is synthesized from glutamate, an 
excitatory neurotransmitter in the brain. Significant GAD67 reduction has been reported 
in the prefrontal cortex in this patient population.13 Akbarian et al. found that cell 
migration in the prefrontal cortex and hippocampus occurred in deeper area in 
schizophrenia compared to controls.14,15 These postmortem findings and Falkai et al.16 
suggest an abnormality in the brain developmental process affecting cortical structure. 
However, postmortem studies have a number of limitations such as the confounding 
effects of medication, aging and other medical illnesses. 
 
1.1.2 Brain imaging (CT, MRI) 
Recent developments in neuroimaging have facilitated the in vivo examination of patients 
and controls. The most consistent finding has been the larger size of the lateral ventricles 
in chronic schizophrenic patients. This abnormality was found in studies using computed 
tomography (CT)17 and magnetic resonance imaging (MRI).18 In terms of the anatomical 
structure, a reduction in size in schizophrenia compared to controls has been reported in 
several regions including the dorsolateral prefrontal cortex, hippocampus, thalamus, 
anterior cingulate and superior temporal gyrus.19  
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Gray matter losses in schizophrenia, compared to normal subjects, were observed in 
several regions in the brain such as the frontal cortex, dorsolateral prefrontal regions, 
hippocampus, and superior temporal gyrus.19 However, findings in gray matter loss have 
not been consistent in terms of the brain region. Thompson et al.20 examined gray matter 
loss in schizophrenia subjects and healthy controls over five years. They showed a 
significant reduction in cortical gray matter in schizophrenia subjects compared with 
controls. This study and several similar longitudinal studies21,22 imply that 
neuroanatomical abnormalities in schizophrenia may be progressive.17 
 
1.1.3 Functional connectivity 
Besides the structural abnormalities in schizophrenia, there has also been research to 
examine the functional connectivity in the brain. Diffusion tensor imaging (DTI) 
techniques provide a view of the connectivity in the brain regions, inferring the 
directional connectivity through the measurement of the apparent diffusion coefficient 
(ADC).23 Many studies have shown the increased myelin density in the white matter, 
suggesting a complex functional connectivity in schizophrenia.24 Functional MRI (fMRI) 
has shown a functional disconnectivity in schizophrenia such as in default network 
studies.25 A default network is considered to be the basic functional connectivity in the 
resting state of the normal brain. A few studies of the default network showed that some 
of the functional connections are abnormal in schizophrenia.26 Bluhm et al.27 reported 
that functional connectivity from the posterior cingulate is significantly weaker or 
unidentified in the first episode schizophrenia patient when compared to healthy 
volunteers.  
Thus, there are a number of structural and functional abnormalities found in many brain 
regions in schizophrenia patients. The heterogeneity of these findings points to a number 
of genetic and environmental factors, all of which may affect final common pathways 
leading to the symptoms of schizophrenia. Among possible final common pathways, 
limbic basal ganglia thalamocortial circuits have been the most studied.28 
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1.1.4 Candidate circuit: Basal ganglia-thalamocortical circuit 
The central nervous system is composed of billions of nerve cells (neurons). The signals, 
such as sensory information, are transmitted as electric stimuli with neurotransmitters, 
which are biochemical compounds, pooled in the axon terminals. 
 
Figure 1-1: Limbic basal ganglia thalamocortical circuit  
AC, anterior cingulate; Cb, cerebellum; Hip, hippocampus; NA, nucleus 
accumbens; Pfc, prefrontal cortex; Th, thalamus; VT, ventral tegmentum. (This 
illustration is adapted from Figure 2-2 in [29])  
Figure 1-1 represents one potential candidate neuronal circuit implicated in schizophrenic 
anomalies, called the limbic basal ganglia thalamocortical (BGTC) circuit. This BGTC 
circuit, one of the basic neuronal pathways in the normal human brain, is considered to be 
a possible candidate circuit for schizophrenia because this circuit is responsible for the 
connections between the brain regions related to schizophrenic symptoms. The anterior 
cingulate is associated with attention and emotional processing.30 The thalamus is 
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considered to be a gateway to the brain since all neuronal signals except olfactory 
information pass through this region. Most of the connections are glutamatergic. 
Glutamate is an amino acid found in many areas of the body, but is abundant in the 
nervous system where it is a major excitatory neurotransmitter. The understanding from 
this candidate circuit in local abnormalities will be extended to the entire brain 
encompassed by the neuronal pathways.  For instance, if significantly higher or lower 
glutamate is observed in the thalamus, it may result in malfunction of the entire candidate 
circuit, composed of glutamatergic connections. 
Another important excitatory neurotransmitter associated with the BGTC is dopamine. In 
this BGTC, dopaminergic neurons project from the ventral tegmentum to the nucleus 
accumbus which is an important node in this pathway. Currently, most medication for 
schizophrenia targets the dopamine neurotransmission.31 Since schizophrenic positive 
symptoms are improved with these medications, dopamine is thought to be a key 
neurotransmitter implicated in this disorder.32  
 
1.1.5 Etiological theories of schizophrenia 
As indicated above, the glutamate and dopamine theories are good candidates for 
investigations to elucidate possible mechanisms of schizophrenia. From a 
pathophysiological point of view, these two hypotheses of schizophrenia will be 
discussed below. The Dopamine Hypothesis is suggested through the effect of 
antipsychotic medication that suppresses psychosis by blocking the dopamine receptor.32 
The Glutamate Hypothesis is suggested by the results of drugs that cause glutamate 
receptor hypofunction. In normal and schizophrenic subjects these drugs induce both 
psychotic symptoms (e.g. hallucinations) and negative symptoms (e.g. flat affect and lack 
of motivation). While the Glutamate Hypothesis has some advantages, there is not a large 
amount of direct evidence suggesting that glutamate is the major cause of schizophrenia. 
It is also possible that both dopamine and glutamate may be involved in the 
pathophysiology of schizophrenia.  
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1.1.5.1 Dopamine hypothesis 
The abuse of drugs that stimulate dopamine often causes hallucinations and delusions that 
resemble the positive symptoms of schizophrenia.33 Dopamine is one of the major 
excitatory neurotransmitters, associated with several functions such as motor activity, 
attention and reward.34 Positron emission tomography studies have shown an increased 
dopamine re-uptake, compared to a control group, in the D2 receptor at the ventral 
tegmentum in schizophrenic subjects as well as psychotic patients.35 Most antipsychotic 
medications block the D2 receptor to prevent binding of the dopamine, resulting in 
significant improvement in psychotic symptoms, but showing less improvement in the 
negative symptoms. Thus, dopamine is most likely involved in schizophrenic symptoms, 
but is not likely the main etiological factor.  
 
1.1.5.2 Glutamate hypothesis 
This thesis has focused on another excitatory neurotransmitter; glutamate. Although 
glutamate is an essential excitatory neurotransmitter in vertebrates, it may be involved in 
the symptoms of schizophrenia. In an animal study, Olney and Farber36 reported that 
phencyclidine, a drug that inhibits the glutamate neurotransmission by blocking the N-
methyl D-aspartate (NMDA) glutamate receptor, could induce schizophrenic-like 
changes. The rats that received phencyclidine demonstrated progressive loss of gray 
matter in regions found to have similar changes in schizophrenia. Curiously patients who 
ingest drugs that block NMDA receptors develop both positive and negative symptoms.37 
Blockage of the NMDA receptor leads to impaired GABAergic activity, which inhibits 
the glutamatergic neurotransmission.   However when GABA activity is impaired there is 
another pathway that is activated that leads to excessive glutamate neurotransmission 
when the NMDA receptor is blocked.    
This excessive glutamate neurotransmission can be toxic to neurons (excitotoxicity), and 
may affect the glutamate pathways in the entire BGTC circuit. This toxic process 
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eventually leads to the neuronal dysfunction, loss of synapses or neuronal death 
(neurodegeneration). Thus we hypothesized that glutamatergic anomalies in 
schizophrenia may lead to limited neurodegeneration associated with a loss of neuropil 
and functional deficits. This theory could explain why schizophrenia symptoms such as 
social withdrawal improved little and often persist throughout the lifetime of the patients.  
 
1.1.6 Neurodevelopment versus Neurodegeneration 
It is unclear at what time point schizophrenia is pathologically evident. Schizophrenic 
symptoms typically appear around adolescence when a family member notices unusual 
behavior or psychotic symptoms. This could coincide with cortical pruning, which may 
uncover an early neurodevelopmental lesion. However, there is a debate over whether 
schizophrenia is a neurodevelopmental or a neurodegenerative disorder. The former 
theory indicates that there are abnormalities before-birth but that these are hidden or 
hardly visible. These problems during gestation lead to a dealignment of the cortical 
layers or abnormal cell migration as indicated above. This neurodevelopmental 
hypothesis suggests that these anomalies do not progress after their manifestation during 
adolescence.38 On the other hand, the neurodegenerative hypothesis suggests that there is 
some sort of degenerating process after the development of psychiatric symptoms in 
schizophrenia subjects.39 This theory has not been widely adopted due to a lack of 
evidence of cell death in schizophrenia.40 For instance, a significant decrease in brain cell 
number is found in several regions in Alzheimer’s disease patients, one of the 
neurodegenerative disorders. Instead of evidence of cell death, loss of neuropil and 
smaller neuronal size in schizophrenia are often reported. However, limited forms of 
excitotoxicity not associated with cell death have been reported.41 Since deteriorating 
social function is one of the clinical criteria in schizophrenia, we hypothesized that 
schizophrenia may be a neurodegenerative disorder as well as a neurodevelopmental 
disorder. To examine this hypothesis, we focused on the neurotransmitter glutamate, 
which possibly leads to neuronal dysfunction. We have selected proton magnetic 
resonance spectroscopy (MRS) to track the glutamatergic metabolites in schizophrenic 
subjects in vivo. 
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1.2 The Investigative Technique: Magnetic resonance 
spectroscopy 
Magnetic resonance imaging and spectroscopy are excellent techniques to measure 
structural and neurochemical changes/differences in vivo as there is no ionizing radiation. 
Thus, serial investigations are possible in both patients and healthy controls.  
 
1.2.1 Principles of magnetic resonance imaging and spectroscopy 
The research groups of Purcell42 and Bloch43 independently introduced the principle of 
nuclear magnetic resonance (NMR) in 1946. They discovered that nucleus in strong 
magnetic field, precess with a certain frequency (Larmor frequency). These precessing 
nuclei could be made to interact with specific radio frequency energies and a nuclear 
signal could be measured. The Nobel Prize in Physics 1952 was awarded jointly to Felix 
Bloch and Edward Mills Purcell "for their development of new methods for nuclear 
magnetic precision measurements and discoveries in connection therewith."  
Building independently on this phenomenon the groups of Lauterbur44 and Mansfield45 
are credited with the discovery of Magnetic Resonance Imaging (independent 
publications in1973). The Nobel Prize in Physiology or Medicine 2003 was awarded 
jointly to Paul C. Lauterbur and Sir Peter Mansfield "for their discoveries concerning 
magnetic resonance imaging."  
 
1.2.1.1 Net magnetization 
Nuclear spins precess at the Larmor frequency (ω0), in a static magnetic field (B0). We 
can write the ‘Larmor equation’ as; ω0 = γB0, where γ is the gyromagnetic ratio (2π × 
42.575 MHz/T for protons). Quantum mechanically, the only allowed orientation of these 
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spins is either parallel or anti-parallel to the field, with the preferred direction being 
parallel. In thermal equilibrium, a Boltzmann distribution can describe the ratio of 
parallel to anti-parallel spins. For example at 1.5T and 37 Celsius, there is an excess of 
only 1 in 100,000 spins that are parallel to the field. It is this spin excess that produces the 
net magnetization (M0) parallel to B0 and ultimately contributes to nuclear signal which is 
used to create an image. This net magnetization vector for most practical applications can 
be treated in a semiclassical formalism, where the motion of the vector in the general 
magnetic field is determined by the phenomenological Bloch equation:43 
, 
where Mz is the longitudinal magnetization, Mxy is the transverse component of the 
magnetization, and T1 and T2 are the spin-lattice and spin-spin relaxation times 
respectively. Bold font (e.g. M, B) refers to vectors.  
 
1.2.1.2 M0 rotation along B1 and FID 
Thus far, only a static magnetic field has been considered in the z direction. It is only 
when the net magnetization vector is perturbed into the transverse (xy) plane that a signal 
is detected in the receive coil, which is oriented in the xy plane. In order to direct the net 
magnetization toward the x-y plane, a rotating magnetic field (B1) is often applied in the 
x direction. This induces a precession of the net magnetization around the B1 vector, and 
eventually into the x-y plane. To rotate in this manner, the frequency of B1 must be tuned 
to the Larmor frequency. As the Larmor frequency is typically in the radio frequency 
(RF) band, the B1 pulse is often referred to as an RF pulse. The rotation speed around B1 
is slower with respect to the Larmor frequency because the B1 magnetic field (e.g. 10 µT) 
is much smaller than the B0 field (e.g. 1.5T). When the RF pulse is turned off, the net 
magnetization vector returns to thermal equilibrium (M0) oriented along the longitudinal 
direction.   
 
(1-1) 
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1.2.1.3 FID, and T1 & T2 relaxation 
The transverse component of this magnetization decreases as the spins lose their phase 
coherence. This decrease in the net transverse component with precession at the Larmor 
frequency is called free induction decay (FID). A FID is always generated when an RF 
pulse is applied. While the longitudinal magnetization gradually recovers with time, the 
transverse components of the spins gradually lose their phase coherence and the net 
transverse magnetization decreases over time. These processes are due to T1 relaxation 
and T2 relaxation, respectively. The re-growth process involves the energy exchange 
between spins and the main kinetic energy of the nuclei through the dipole-dipole 
interaction. A T1 process requires a magnetic field fluctuating near the Larmor 
frequency. This oscillating magnetic field is generated by another proton or electron in 
the same molecule or different molecule tumbling or moving with a frequency near the 
Larmor frequency. T1 is the time that the longitudinal magnetization recovers from zero 
to 63% of its equilibrium value after the end of the 90 degree RF pulse.  
T2 is the decay time associated with the magnetization dephasing process in the 
transverse plane. Phase coherence decreases quickly when the magnetic field fluctuation 
induced by molecular motion or tumbling is much slower than the Larmor frequency. To 
have an effect on the magnetization in the x-y plane these fluctuations must be along the 
z axis. T2 is the time that the transverse component decreases to 37% after the RF pulse. 
If the molecule tumbling rate or movement is much faster than the Larmor frequency, T2 
in this environment becomes longer and eventually approaches T1. In this case, the static 
dephasing originating in the local magnetic fields experienced by the spins is removed, 
because the local magnetic fields are averaged due to “motional averaging.”  
 
1.2.1.4 Selective excitation (slice selection), gradients 
In order to rotate the net magnetization vector into the x-y plane, the magnetic field B1 
must be maintained for a time, t, such that γ B1 t = π/2. This would tilt spins throughout 
the entire volume through π/2, and is referred to as a 90 degree pulse. In order to rotate 
the magnetization through 180 degrees, this same RF pulse could be applied, but 
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maintained for a duration 2t. In order to excite a particular slice however, a linear 
magnetic field gradient is required. This gradient creates a linear variation in the 
magnetic field with respect to position, for example along the z-direction. With such a 
linear gradient, the resonant frequency of the hydrogen nuclei varies depending upon 
their physical location along the z-direction. While these gradients are active, the physical 
slice of interest corresponds to a bandwidth of frequencies. In order to excite only those 
spins corresponding to the physical slice, the RF pulse is typically shaped with a sinc 
waveform such that a pulse with a particular frequency bandwidth can be generated. As 
mentioned earlier, it is only when the net magnetization is directed into the x-y plane that 
the FID is detected by the hardware. It is these signals that must be collected to form an 
image.   
The proton signals are received by a coil, the cross-sectional area of which is set 
perpendicular to the transverse plane. This RF coil is often the equivalent of a coil of wire 
tuned to the resonant frequency (the Larmor frequency). Often so called birdcage 
resonators or birdcage coils are used in MRI, primarily for transmission of signal. A 
complete description of these coils is beyond the scope of this thesis. However these coils 
have good uniformity, and are cylindrical coils, placed in parallel with the main magnetic 
field, and hence the bore of the MRI. These coils are a great advantage in MRI because 
they can generate transverse magnetic fields while allowing a body to placed along the 
cylindrical axis. For simplicity however, the signal detection will be considered to be 
strictly from a simple solenoid.  
Once the magnetic field is directed toward the transverse plane, it begins to precess 
around the static field B0. Following a 90 degree pulse, the precessing magnetization 
vector represents a rotating magnetic field that induces an oscillating signal in the RF 
coil. This signal is the free induction decay. The decay of the magnetization is 
characterized using the relaxation time T2*, which is composed of T2 and the magnetic 
field inhomogeneity, which is determined by the magnetic field stability, quality of 
shimming, and so on.  T2* is often written as: 
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, 
where T2’ is the contribution to the decay due to magnet inhomogeneities, and other 
susceptibility issues such as air-tissue interfaces, iron concentration, etc. 
  
1.2.1.5 Fourier transform (time ↔ frequency) 
Time and frequency, and similarly object space and spatial frequency are intimately 
related through the Fourier Transform. The Fourier Transform, F(ω) of a function, f(t), is 
given by: 
, 
and a similar relationship can be defined between a function in image space, f(x), and its 
Fourier Transform in spatial frequency (or “Fourier”) space, F(kx). It turns out that the 
MRI signal is related to the magnetization intensity through a Fourier transform. To 
illustrate this relationship, it is instructive to first consider the process of phase and 
frequency encoding in a simple spin echo MRI experiment.  
 
1.2.1.6 Frequency-encoding & phase-encoding (MRI) 
A simple spin echo (SE) experiment is illustrated in Figure 1-2. The Readout gradient, or 
x-gradient, applied at the time of signal readout causes the resonant frequency (ω(x)) to 
vary with x-position according to: 
, 
where ω0 is the Larmor frequency, γ is the gyromagnetic ratio, and Gx is the x- (readout) 
gradient.   
(1-2) 
(1-3) 
(1-4) 
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Figure 1-2: MRI Sequence Diagram of a simple Spin-Echo 
(Adapted from [46] ) 
This gradient is often referred to as the frequency encoding gradient. According to Figure 
1-2, a phase, or y-gradient (Gy), is applied shortly after the initial 90 degree pulse; 
however it is applied in a different manner than the x-gradient. Gy is applied for a fixed 
time, ty, and the entire sequence is repeated a number of times, each with a different 
gradient magnitude. During the time ty, the spins are given a different phase ωty, 
depending upon their y position: 
. 
Each time the sequence is repeated with a different Gy, the spins are given a different 
amount of phase encoding. This sequence is repeated N times, and an echo is recorded 
with M points, generating a matrix (N × M) of echo's that differ by the amount of phase 
encoding. When this block of data is 2D Inverse Fourier Transformed, the image 
information is recovered. Rather than strictly imaging, MR spectroscopy isolates a signal 
from a particular region in the volume. When this time varying proton signal is Fourier 
(1-5) 
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transformed, it now turns out to be a spectrum in the frequency domain. The full width at 
half maximum of the spectrum is determined by (πT2*)-1.  
 
1.2.1.7 Sampling rate, image resolution  
Spatial frequency is the inverse (Fourier) space with respect to object space. The spatial 
frequencies are defined in terms of the readout gradient amplitude, Gx, and the phase 
encoding step, Gy, as: 
, 
. 
Note that in order to sample the spatial frequencies, time, t, is varied to sample kx, 
however the gradient amplitude, Gy, is varied to sample ky (ty is a constant). The simplest 
definition of resolution is to divide the Field Of View (FOV) into Nx or Ny segments, so 
that the resolution, δx and δy are given by: 
. 
Because position and spatial frequency form a Fourier pair, the width in object space 
(FOV) is inversely related to the resolution in the frequency space (∆k): 
. 
By the same argument however, the extent or width in the frequency domain (Wkx and 
Wky) should be related to the inverse of the resolution in the spatial domain. With the 
assumption that the widths in the frequency domain are: 
. 
(1-6) 
(1-7) 
(1-8) 
(1-9) 
(1-10) 
15 
 
Equations (1-8) through (1-10) show that δx = 1/Wkx and δy = 1/Wky as expected. Using 
equations (1-6) and (1-7), expressions can be easily derived for ∆kx and ∆ky, the 
sampling period: 
, 
, 
where it is now explicit that increments in kx are related to increments in the digitizer 
resolution (∆t), and increments in ky are related to increments in the phase encode 
gradient (∆Gy). These expressions can then be used for a given pulse sequence to derive a 
relationship between the pulse parameters and the FOV, resolution, and sampling rate. 
 
1.2.1.8 Introduction of MRS physics, chemical shift 
While MRI is composed primarily of the signals from the hydrogen nuclei of the water 
molecules, magnetic resonance spectroscopy is closely related to the signals from the 
hydrogen groups in the chemical structure of the sample or region. Frequencies of these 
hydrogen groups are off-resonance from the Larmor frequency of water protons. One of 
the primary contributors to this off-resonance is the chemical shielding, or chemical shift. 
Because electrons on molecules can also become polarized in a magnetic field, the actual 
field, and therefore the resonant frequency at the nucleus (ωeff) will be less due to this 
chemical shielding (σ):  
, 
where σ is the isotropic chemical shielding. In a full quantum mechanical treatment, σ is 
a tensor quantity. For a simple molecule that can be either parallel (σa) or antiparallel (σb) 
to the field, the chemical shielding can be written in terms of an isotropic and an 
anisotropic term: 
(1-11) 
(1-12) 
(1-13) 
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. 
However in a liquid, the molecules will sample all orientations, and will average to zero 
the anisotropic chemical shielding. The chemical shift, δ, in parts per million (ppm) is 
defined as the shielding with respect to a reference, or equivalently, the shift in frequency 
with respect to a reference: 
, 
where in brain proton MRS, the reference is usually chosen such that NAA = 2.01 ppm. 
A phenomenon that generates a fine structure in the NMR spectrum is J-coupling. J-
coupling or indirect dipole-dipole coupling is an electronic nuclear interaction between 
the electrons in a molecule and the hydrogen nucleus, which generates off-resonance 
perturbations from the proton Larmor frequency. The degree of off-resonance effects 
depends upon the chemical structure, and the organization of hydrogen nuclei in the 
molecule. In addition, the spectral shape is no longer a single peak – this interaction 
introduces a fine structure to the spectrum. The number of peak splittings is determined 
by the hydrogen groups in the molecular neighborhood.  
Because protons have a nuclear spin ½, they are restricted to either the spin up or the spin 
down state. If a neighboring proton spin is exposed to this local field, then the spins of 
the hydrogen nuclei will precess either faster or slower than the resonant frequency, 
depending upon whether this proton neighbor is spin up or spin down. As a result, the 
spectrum for this single proton is split into a pair of peaks called a doublet. Peaks can also 
be split by multiple protons in a side group, and peaks can be split into doublets, triplets, 
etc. This phenomenon is called J-coupling and the distance of the splitting is called the J-
coupling constant expressed in Hertz. It is mainly because of the chemical shift, and J-
(1-14) 
(1-15) 
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coupling, that the various metabolites can be identified based upon their unique spectral 
signature. 
 
1.2.2 Magnetic resonance spectroscopy 
In general, there are two types of spectroscopy sequences, single and multiple voxel. A 
single voxel sequence is composed of three RF pulses, each coincident with their own 
slice selective gradient applied in each of the Cartesian axes.  This process selects three 
perpendicular slices, with the selected volume corresponding to the intersection of these 
slices. The most common single voxel spectroscopy sequences are stimulated echo 
acquisition mode (STEAM) and point-resolved spectroscopy (PRESS). Chemical shift 
imaging (CSI) and magnetic resonance spectroscopic imaging (MRSI) are common 
multi-voxel type sequences. While the data are collected from much larger regions 
compared to single voxel spectroscopy, each volume tends to be bigger and the total data 
acquisition time is much longer.  
 
1.2.2.1 STEAM vs. PRESS sequences 
Both STEAM and PRESS sequences are composed of three RF pulses. Each RF pulse 
results in a free induction decay, each combination of two RF pulses produces a spin-
echo and three RF pulses create a stimulated echo as well as a double spin-echo. While a 
stimulated echo is the primary signal to be detected in STEAM sequences, a double spin-
echo is the primary signal to be detected in PRESS sequences.  
The STEAM sequence, depicted in Figure 1-3, is composed of three 90 degree RF pulses, 
preceded by a CHEmical Shift Selective (CHESS) pulse. The RF pulses create one 
stimulated echo (STE), three FIDs, three single spin-echoes, and one double spin-echo. 
Because the stimulated echo is the only signal used, the other FIDs and spin-echoes are 
spoiled using crushing gradients, dephasing their transverse magnetizations, so that they 
do not contribute to the overall signal.  
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Figure 1-3: STEAM Sequence Diagram 
The black rectangles represent spoiling gradients. The gray rectangles represent 
slice selective gradient with refocusing gradient. (Adapted from [47]) 
In theory, the signal completely recovers to the original amplitude in a PRESS sequence 
while only half of the original signal is detected in the STEAM sequence. After the first 
90 degree RF pulse in the STEAM sequence, the spins in the transverse plane (x-y plane) 
dephase during the TE/2 period. For illustration, it can be assumed that the magnetization 
is composed of 4 spins, their directions 90 degrees apart from each other on the 
transverse plane after these spins dephase in the rotating frame of reference. The second 
90 degree pulse flips these dephased spins to the y-z plane perpendicular to the transverse 
plane. The two components on the y-axis dephase due to the crushing gradient during the 
mixing time (TM) period. The third RF pulse rotates the spins along the longitudinal axis 
onto the transverse x-y plane again. The MR signal is maximized at TE/2 after the last RF 
pulse. However, the amplitude of this signal is a half of the original signals because the 
other two transverse spins were dephased during the TM period.  
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The PRESS sequence in Figure 1-4, on the other hand is composed of one 90 degree and 
two 180 degree RF pulses. Unlike the STEAM sequence, the double spin-echo (DSE) is 
the primary signal in the PRESS sequence. 
 
Figure 1-4: PRESS Sequence Diagram 
The black rectangles represent spoiling gradients. The gray rectangles represent 
slice selective gradients. (Adapted from [47]) 
With a PRESS sequence, the dephasing spins are rephased at every TE/4 following a 180 
degree pulse. Balanced gradients are implemented before and after the RF pulse. In 
practice, the signal does not fully recover due to an imperfect slice profile, which is the 
Fourier Transform of the RF pulse. A perfect slice profile is a rectangular shape, in which 
all spins within the range are excited with the desired flip angle. The Fourier Transform 
of a sinc function of infinite extent is a rectangular function. However, since the RF pulse 
is implemented in a finite time, the slice profile is not a perfect rectangular shape, with 
ringing artifacts at the edges of the slice profile.  
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Optimizing the slice profile of a 180 degree pulse is more difficult than designing the 
slice profile of 90 degree pulses. In the worst case scenario, only a small portion of the 
spins around the center of the slice profile rotate through 180 degrees but the others rotate 
with different flip angles. Another disadvantage of the PRESS sequence is that metabolite 
signals are sensitive to J-coupling, particularly at longer echo times. 180 degree RF 
pulses induce spin flips in the neighboring protons and change the metabolite peak 
shapes, a process called J-evolution.48 For example, the coupling constant between the 
methyl protons and methine proton of lactate is approximately 6.9Hz. The doublet peak 
representing the methyl group at 1.3ppm appears negative at 1/J (~144ms) and positive at 
2/J (~288ms) using the PRESS sequence.   
 
1.2.2.2 Quantification Methods 
Spectral fitting is performed either in the time domain or in the frequency domain. Time 
domain fitting, such as Singular Value Decomposition (SVD)49 or Hankel-Lanczos SVD 
(HLSVD),50,51 is often used to subtract the remnant water resonances. Although these 
methods are user-independent, they only seek the best mathematical combination of the 
resonances, which does not take any biological meanings into account. Thus, SVD and 
HLSVD are powerful techniques to subtract unnecessary resonances but these methods 
are insufficient to perform an in vivo spectral fitting.  
The linear combination model (LCModel) is the most common spectral fitting technique 
in in vivo MRS.52 LCModel seeks the best compromise for the sum of these components 
in the frequency domain using a model, composed of the metabolite peaks and their 
concentration levels obtained from in vitro experiment. This type of model is referred to 
as an “a priori knowledge” model. The detected MR signal is a summation of the 
sinusoids with an exponential decay. With setting a range of the parameters, such as the 
amplitude and phase of the damped sinusoids, a priori knowledge maintains a realistic 
metabolite levels and their biological combination in the metabolite quantification. 
Although LCModel is used in the frequency domain, the metabolite components in the a 
priori knowledge are the Fourier Transformed time domain signals.  
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Spectral fitting with a prior knowledge is also available in the time domain. The 
algorithm seeks the minimum difference between the raw data and the model (i.e. the a 
prior knowledge) in the time domain by adjusting the unconstrained parameters such as 
the amplitude of the components. As described in “Spectral fitting” in the next section, 
we have chosen to do the time domain fitting with the Levenberg-Marquardt algorithm. 
 
1.2.2.3 Research Methodology 
Since all relevant data were collected and processed in the same manner, the detailed 
methodologies including data collection, pre-processing, spectral fitting and 
quantification methods are described in this section.  
 
1.2.2.3.1 Equipment, MRI and MRS sequences 
All MR data were collected with a 4.0 Tesla Varian (Palo Alto, California, 
USA)/Siemens (Erlangen, Germany) whole body scanner with a Varian Unity Inova 
console and Siemens Sonata gradients, located at the Centre for Functional and Metabolic 
Mapping of the Robarts Research Institute, London, Ontario, Canada. A transmit and 
receive, circularly polarized birdcage head coil (XLR Imaging Inc., London, Ontario 
Canada) was used throughout our studies. The volunteer’s head was placed inside of the 
head coil and set at the center of the head coil aligned with the subject’s eyebrows. 
Global shimming was manually performed with the first and second order shims to 
reduce the magnetic field inhomogeneity.  
A sagittal scout image was taken to plan the center of the transverse slices which cover 
the entire head. The center slice passed through the genu of the corpus callosum and the 
dorsal end of the splenium of the corpus callosum. Then, T1 weighted transverse images 
were collected with a 3D MP-RAGE sequence which is a three-dimensional 
magnetization prepared fast low angle shot (FLASH) sequence, flip angle = 30 degrees, 
TR = 11.4 ms, TE = 6.2 ms, inversion time (TI) = 500 ms, matrix size = 256 × 256, field of 
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view = 20 × 20 cm2, resolution = 0.78 × 0.78 mm2, 64 contiguous slices of 
thickness = 2.75 mm.  
Using those T1-weighted images, the 10 × 15 × 10 mm3 (right-left, anterior-posterior, 
inferior-superior direction) spectroscopy voxels were positioned in the left anterior 
cingulate (Brodmann Area (BA) 32 & 24) and the left thalamus. MR spectroscopy data 
were acquired with a single voxel STEAM sequence (TE = 20 ms, mixing time 
(TM) = 30 ms, TR = 2000 ms, dwell time = 500µs, 8 step phase-cycling) with a chemical 
shift selective pulse (CHESS) for water suppression. After the voxel localization, 90 
degree RF pulse powers were optimized and local shimming was manually performed 
with a water unsuppressed spectrum. The CHESS pulse, which was composed of three 
Gaussian RF pulses, was turned on to optimize the RF power and pulse length. 
Metabolite data were acquired with water suppression (256 averages), followed by the 
water unsuppressed data (16 averages). This MRS procedure was conducted in the left 
anterior cingulate and the left thalamus.  
 
1.2.2.3.2 Pre-processing 
Water suppressed data were corrected for eddy current and the spectrum line shape with 
the QUality and Eddy Current Correction (QUECC) technique,53 which is a combination 
of the “QUAntification improvement by converting LIneshapes to the Lorentzian TYpe” 
QUALITY54 and “Eddy Current Corrections” (ECC), using the water reference spectrum. 
QUALITY deconvolution was performed on the first 400 complex points (100ms) in the 
time domain and ECC was performed on the rest of the complex points. Residual water 
resonances (4.2 - 6.2 ppm) were subtracted using the HLSVD algorithm.51,55,56 
 
1.2.2.3.3 Spectral fitting 
Pre-processed data were fit using in-house software called Fitman56,57 (Lawson Health 
Research Institute) to the first 1024 complex points (512ms) in the time domain. The 
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fitting procedure was based on the Levenberg-Marquardt methods to minimize the 
differences between raw data and the prior knowledge. Our model was created with the 
twelve metabolites from in vitro measurement and eleven macromolecules from literature 
values. 58,59 Each metabolite spectrum was composed of single Lorentzian peaks while 
macromolecule spectra were Gaussian. Our template is composed of 247 single peaks 
with six parameters; chemical shift, amplitude (signal intensity at t = 0), Lorentzian 
linewidth, phase, delay time, and Gaussian linewidth. To reduce the time to find the 
global minimum, all parameters except amplitude are constrained in our model.   
 
1.2.2.3.4 Metabolite quantification and volumetric analyses 
Metabolite concentration levels are quantified using the internal water reference. 
Corresponding signal amplitudes are summed for each metabolite to express the peak 
area. Metabolite concentration levels were calculated using the following formulae60: 
 
 
 
 
where Area is the peak area of spectrum, Averages is the number of transients, Gain 
represents the receiver gain, # of 1H is the number of proton nuclei in the molecule (i.e. # 
of 1H
 water is 2), scaling factor is the scaling (e.g. 10-4) of the raw data, Water density 38C is 
the density of water at human body temperature, and Water
 molecular weight 38C is the 
(1-16) 
(1-17) 
, 
, 
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molecular weight of water at human body temperature. Metabolite peak area is divided 
by the water peak area since water is set as the internal reference with the concentration 
level 55.5556 [Mol / l ]. Water percentage is adjusted by the brain tissue fraction in the 
spectroscopy voxel because of different water percentage in each brain tissue: 81% in the 
gray matter (GM), 71% in the white matter (WM), and 100% in the cerebral spinal fluid 
(CSF).61 There is an assumption that no metabolite exists in the CSF. The denominator 
(1 - f CSF) is required to correct the water signal from the CSF. This adjustment is limited 
for the small CSF fraction in the spectroscopy voxel.  
The fraction of the brain tissue is calculated from each spectroscopy voxel (1.5 cm3) with 
ANALYZE and in-house software called Xstatpack, developed by J Davis. The detailed 
segmentation analysis is described in the Methods section in Chapter 3.  
Volumetric changes in gray matter were measured with voxel-based morphometry 
(VBM)62,63 on the T1-weighted anatomical images using Statistical Parametric Mapping 
(SPM) (Wellcome Department of Imaging Neuroscience, University College London, 
UK). Normalization was performed on all images with the T1-weighted template 
developed by the Montreal Neurological Institute. Images were segmented into gray, 
white and CSF compartments. Segmented images were then modulated using the 
Jacobian determinants, created in the normalization step. Lastly, images were smoothed 
with an isotropic Gaussian filter of 12mm full width at half maximum. A general linear 
model with t-statistics was applied for the statistical comparisons. 
 
1.2.3 Techniques and Disease: MRS findings in schizophrenia 
Abnormal glutamatergic metabolite levels have been found in cross-sectional 
schizophrenia studies using 1H MRS. Significantly elevated glutamine levels in the 
anterior cingulate were found in never-treated schizophrenia patients64 and in patients at 
high risk to develop psychosis.65 Tibbo et al. 66 reported a higher glutamate/glutamine 
ratio in the right medial frontal lobe in patients at high generic risk compared to those at 
low risk for schizophrenia. In the thalamus, Théberge et al.62 found an increased 
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glutamine level in schizophrenia while Stone et al.65 reported a decreased glutamate level 
in high-risk mental state patients. In the chronic studies, significantly decreased 
glutamate and/or glutamine levels were found in the anterior cingulate.67-70 Théberge et 
al.70 also reported a significantly increased glutamine level in the thalamus in chronic 
schizophrenia patients.   
One of the issues with 1H MRS measures of glutamate is that only 15-20% of the 
glutamate MR signals are involved in the neurotransmission and the rest of the signals 
come from the pooled glutamate in the vesicle,71 which does not have the same toxicity 
as the glutamate released into the synaptic cleft. For this reason, the focus of this thesis 
has been on measuring glutamine, a precursor of glutamate. Glutamate neurotransmitters 
in the synaptic gap are taken up by the glial cells, converted to glutamine, synthesized 
again to glutamate and pooled in the vesicle in the axon terminals. While 80% of the 
glutamate MR signal comes from the pooled glutamate in the neurons, most of the 
physiologically active glutamate comes from glutamine produced in glial cells.71 
Therefore, glutamine may be a better indicator of the glutamate neurotransmission 
although part of the pool of glutamate also arises from glucose via the tricarboxylic acid 
cycle.72 
Phosphorous magnetic resonance spectroscopy (31P MRS) allows the investigation of 
neuronal damage, which may be caused by excitotoxicity. Phosphorous MRS is a useful 
technique to observe the energy metabolism and cell membrane phospholipid 
metabolism. Phosphocreatine (PCr) and inorganic phosphorous (iP) indicate the energy 
metabolism. Phosphomonoesters (PME) and phosphodiesters (PDE) indicate the 
phospholipid synthesis and membrane breakdown products. While significantly 
decreased PME and increased PDE were found in the first episode studies,73,74 the 
phospholipid membrane metabolism showed an increased, decreased or even normal 
levels in chronic studies.75-77     
Both 1H and 31P MRS findings are inconsistent in the chronic studies. This 
inconsistency may be due to the variability in type and dose of medication used to treat 
these patients. Longitudinal studies, however, are required to observe the disease process. 
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Using 1H MRS, Théberge et al.60 examined seventeen never-treated schizophrenia 
patients and completed their 30 month follow-up scans. It was reported that at the onset 
there was an increased glutamine level in the patients compared to the healthy volunteers, 
however those elevated glutamine levels were decreased in schizophrenia over the 30 
month assessments. In a longitudinal 31P MRS study, Miller et al.78 reported an elevated 
PME in first episode schizophrenia patients compared to controls, with a significantly 
decreased PDE in schizophrenia patients at the 30 month assessment when compared 
with their initial assessment.  
These two longitudinal studies suggest a degenerative process in the first few years in 
schizophrenia. However, several key questions are raised by these studies:  
 
1. First, how long does this process persist in schizophrenia? Chapter 2 of this thesis is 
an extension of the previous longitudinal study (Théberge et al.60) to investigate 
whether these results persist out to 80 months.  
2. Secondly, are metabolite levels such as glutamatergic metabolites and NAA affected 
by structural changes in the brain? To address this question, the third chapter of this 
thesis is designed to probe whether or not changes in the gray matter in the 
spectroscopy voxel could be associated with observed changes in metabolite levels. 
3. Lastly, it was noted from our long-term study that due to a hardware modification, 
there was a change in the noise level of the system. Hardware replacements and/or 
upgrades are inevitable, particularly as the duration of a study becomes longer.  
Although our MR technician carefully maintained the MR system, with rigorous 
quality control, this change in the system noise may have affected the metabolite 
signal-to-noise ratio in our study.  Thus the third and final question is:  Did the signal-
to-noise ratio change due to this hardware modification, and was the metabolite 
quantification affected? Chapter 4 represents a series of data manipulations and 
simulations which were designed to answer this question.  
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1.3 Hypotheses 
1. Significantly higher glutamatergic metabolites during the first episode will decrease 
in schizophrenia in a time course. Glutamatergic metabolite decreases will correlate 
with widespread gray matter losses and social functioning at a 7 year follow-up 
(Chapter 2). 
2. Loss of glutamatergic metabolites in first episode patients over time will be related to 
gray matter loss in the voxel of interest but will not be significantly affected by 
signal-to-noise changes associated with gray matter loss. NAA levels will be less 
likely to be affected by gray matter loss in the voxel of interest or signal-to-noise 
changes (Chapter 3).  
3. Significant differences in brain metabolites observed in our long-term study would 
persist after the data manipulation to simulate a constant signal-to-noise ratio 
throughout this study. Signal-to-noise ratio may be maintained in a reasonable range 
during our long-term study (Chapter 4). 
 
1.4 Overview of the thesis 
This thesis is composed of two clinical studies (Chapters 2 and 3), and one technical 
study (Chapter 4). Chapter 2 has been accepted, and the other two chapters (Chapter 3 
and 4) will be submitted for publication.  
Chapter 2 contains a long term follow-up schizophrenia study using in vivo proton 
magnetic resonance spectroscopy. Eighty month follow-up scans were performed with 
the same schizophrenia patients as in our 30 months study to see if the deterioration 
persists in this disease. This manuscript has been accepted by British Journal of 
Psychiatry.   
Chapter 3 contains a study to examine the metabolite levels adjusted by the amount of 
gray matter in the spectroscopy voxel. Significantly decreased metabolite levels and the 
amount of gray matter were observed in the long term study, presented in Chapter 2. This 
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analysis shows whether the loss of gray matter in the spectroscopy voxel is responsible 
for the changes in the metabolite levels. 
Chapter 4 contains a technical study to examine how the MR signal-to-noise ratio affects 
the metabolite quantification. Metabolite signal-to-noise ratios tended to be higher in the 
first two years of the 80 months follow-up study (Chapter 2). A possible explanation is 
related to a hardware replacement, which is one of the potential confounding factors to 
consider, particularly as the length of a longitudinal study grows. To assess this issue, 
data manipulation in the corresponding data sets and noise simulation were performed to 
see the influence of signal-to-noise ratio as well as the precision of the metabolite 
quantification.  
Chapter 5 is a summary chapter to discuss the entire results (Chapter 2 to 4) and future 
work.  
Appendix A contains preliminary work to compare mood disorder and schizophrenia 
using the same methodology described in Chapter 2. These mental diseases are often 
misdiagnosed due to an overlap in the clinical symptoms.  
Appendix B describes the methodology used in this thesis.  
Appendix C presents a sample spectrum. 
Appendix D contains the ethics approval. 
 
1.5 References 
1. Kraepelin E. Dementia praecox and paraphrenia (1919). Barclay RM, translator; 
Robertson GM, editor. Huntington, New York: Robert E Krieger; 1971.  
2. Bleuler EP. Dementia Praecox or the Group of Schizophrenias (Dementia Praecox 
oder Gruppe der Schizophrenien). New York: International Universities Press; 1950 
(original 1911). 
29 
 
3. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for 
DSM-IV Axis I Disorders (SCID). New York: New York State Psychiatric Institute, 
Biometrics Research; 1997. 
4. Cardno AG, Gottesman II. Twin studies of schizophrenia: from bow-and-arrow 
concordances to star wars Mx and functional genomics. Am J Med Genet. 
2000;97(1):12-7. 
5. Mednick SA, Huttunen MO, Machón RA. Prenatal influenza infections and adult 
schizophrenia. Schizophr Bull. 1994;20(2):263-7. 
6. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: 
historical and meta-analytic review. Am J Psychiatry. 2002;159(7):1080-92. 
7. Kovelman JA, Scheibel AB. A neurohistological correlate of schizophrenia. Biol 
Psychiatry. 1984;19(12):1601-21. 
8. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal 
thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry. 
1990;47(11):1023-8. 
9. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density 
in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and 
occipital area 17. Arch Gen Psychiatry. 1995;52(10):805-18; discussion 819-20. 
10. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small 
interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective 
patients. Arch Gen Psychiatry. 1991;48(11):996-1001. 
11. Akbarian S, Huang HS. Molecular and cellular mechanisms of altered 
GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 
2006;52(2):293-304. 
12. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. 
Nat Rev Neurosci. 2005;6(4):312-24. 
13. Woo TU, Kim AM, Viscidi E. Disease-specific alterations in glutamatergic 
neurotransmission on inhibitory interneurons in the prefrontal cortex in 
schizophrenia. Brain Res. 2008;1218:267-77. 
14. Akbarian S, Bunney WE Jr, Potkin SG, Wigal SB, Hagman JO, Sandman CA, Jones 
EG. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase 
cells in frontal lobe of schizophrenics implies disturbances of cortical development. 
Arch Gen Psychiatry. 1993;50(3):169-77. 
15. Akbarian S, Viñuela A, Kim JJ, Potkin SG, Bunney WE Jr, Jones EG. Distorted 
distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in 
30 
 
temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen 
Psychiatry. 1993;50(3):178-87. 
16. Falkai P, Bogerts B. Cytoarchitectonic and developmental studies in schizophrenia. 
In: Kerwin R, editor. Cambridge Medical Reviews: Neurobiology and Psychiatry. 
Vol 2. Cambridge, UK: Cambridge University Press; 1993. p. 43-70. 
17. Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ. Lateral cerebral ventricular 
enlargement in chronic schizophrenia. Arch Gen Psychiatry. 1979;36(7):735-9. 
18. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in 
schizophrenia. Schizophr Res. 2001;49(1-2):1-52. 
19. DeLisi LE. The concept of progressive brain change in schizophrenia: implications 
for understanding schizophrenia. Schizophr Bull. 2008;34(2):312-21. 
20. Thompson PM, Vidal C, Giedd JN, Gochman P, Blumenthal J, Nicolson R, Toga 
AW, Rapoport JL. Mapping adolescent brain change reveals dynamic wave of 
accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U 
S A. 2001;98(20):11650-5.  
21. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Brans R, Carati I, Rais M, 
Kahn RS. Progressive brain volume loss in schizophrenia over the course of the 
illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry. 
2008;63(1):106-13. 
22. Takahashi T, Wood SJ, Yung AR, Soulsby B, McGorry PD, Suzuki M, Kawasaki Y, 
Phillips LJ, Velakoulis D, Pantelis C. Progressive gray matter reduction of the 
superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry. 
2009;66(4):366-76. 
23. Lim KO, Helpern JA. Neuropsychiatric applications of DTI - a review. NMR 
Biomed. 2002;15(7-8):587-93. 
24. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum 
J, Haroutunian V. White matter changes in schizophrenia: evidence for myelin-
related dysfunction. Arch Gen Psychiatry. 2003;60(5):443-56. 
25. Gusnard DA, Raichle ME, Raichle ME. Searching for a baseline: functional imaging 
and the resting human brain. Nat Rev Neurosci. 2001;2(10):685-94. 
26. Garrity AG, Pearlson GD, McKiernan K, Lloyd D, Kiehl KA, Calhoun VD. 
Aberrant "default mode" functional connectivity in schizophrenia. Am J Psychiatry. 
2007;164(3):450-7. 
27. Bluhm RL, Miller J, Lanius RA, Osuch EA, Boksman K, Neufeld RW, Théberge J, 
Schaefer B, Williamson P. Spontaneous low-frequency fluctuations in the BOLD 
31 
 
signal in schizophrenic patients: anomalies in the default network. Schizophr Bull. 
2007;33(4):1004-12. 
28. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: 
parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog 
Brain Res. 1990;85:119-46. 
29. Williamson P. Mind, brain, and schizophrenia. Oxford: Oxford University Press; 
2006. 
30. Vogt BA, Regions and Subregions of the Cingulate Cortex. In: Vogt BA, editor. 
Cingulate Neurobiology and Disease. Oxford: Oxford University Press; 2009. p. 3-
36. 
31. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. 
Synapse. 1987;1(2):133-52. 
32. O'Donnell P, Grace AA. Dysfunctions in multiple interrelated systems as the 
neurobiological bases of schizophrenic symptom clusters. Schizophr Bull. 
1998;24(2):267-83. 
33. Curran C, Byrappa N, McBride A. Stimulant psychosis: systematic review. Br J 
Psychiatry. 2004;185:196-204. 
34. Schultz W. Reward signaling by dopamine neurons. Neuroscientist. 2001;7(4):293-
302. 
35. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic 
dopaminergic dysfunction in schizophrenia: a positron emission tomographic 
[18F]fluorodopa study. Arch Gen Psychiatry. 2004;61(2):134-42. 
36. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen 
Psychiatry. 1995;52(12):998-1007. 
37. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger 
GR, Bowers MB Jr, Charney DS. Subanesthetic effects of the noncompetitive 
NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, 
and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214. 
38. Weinberger DR. From neuropathology to neurodevelopment. Lancet. 
1995;346(8974):552-7. 
39. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and 
neurobiological perspective. Biol Psychiatry. 1999;46(6):729-39. 
40. Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic 
resonance imaging morphometry: what is happening in the schizophrenic brain? 
Arch Gen Psychiatry. 2002;59(6):553-8. 
32 
 
41. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci. 1999;22:105-
22. 
42. Purcell EM, Torrey HC, Pound RV. Resonance Absorption by Nuclear Magnetic 
Moments in a Solid. Phys Rev. 1946;69(1-2):37–8. 
43. Bloch F. Nuclear Induction. Phys Rev. 1946;70(7-8);460–74. 
44. Lauterbur PC. Image formation by induced local interactions: examples employing 
nuclear magnetic resonance. Nature. 1973;242:190-1.  
45. Mansfield P, Grannell PK. NMR ‘diffraction’ in solids? J Phys C: Solid State Phys. 
1973;6:L422–L427. 
46. Brown MA, Semelka RC. MRI: basic principles and applications. 3rd ed. Hoboken, 
N.J. : Wiley-Liss; c2003. 
47. Mandal PK. Magnetic Resonance spectroscopy (MRS) and its application in 
Alzheimer’s Disease. Concepts Magn Reson Part A Bridg Educ Res. 
2007;30A(1):40-64. 
48. Ernst T, Hennig J. Coupling effects in volume selective 1H spectroscopy of major 
brain metabolites. Magn Reson Med. 1991;21(1):82-96.  
49. de Beer R, van Ormondt D. Analysis of NMR data using time domain fitting 
procedures. In: Diehl P, Fluck E, Gunther H, Kosfeld R, Seelig J, editors. NMR 
Basic Principles and Progress. Vol 26. Berlin: Springer-Verlad; 1992. p. 201–248.  
50. Barkhuisen H, de Beer R, van Ormondt D. Improved algorithm for noniterative 
time-domain model fitting to exponentially damped magnetic resonance signals. J 
Magn Reson. 1987;73:553-57. 
51. van den Boogaart A, Ala-Korpela M, Jokisaari J, Griffiths JR. Time and frequency 
domain analysis of NMR data compared: an application to 1D 1H spectra of 
lipoproteins. Magn Reson Med. 1994;31(4):347-58. 
52. Provencher SW. Estimation of metabolite concentrations from localized in vivo 
proton NMR spectra. Magn Reson Med. 1994;30;672–9. 
53. Bartha R, Drost DJ, Menon RS, Williamson PC. Spectroscopic lineshape correction 
by QUECC: combined QUALITY deconvolution and eddy current correction. Magn 
Reson Med. 2000;44(4):641-5. 
54. de Graaf AA, van Dijk JE, Bovée WM. QUALITY: quantification improvement by 
converting lineshapes to the Lorentzian type. Magn Reson Med. 1990;13(3):343-57. 
33 
 
55. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate 
and efficient quantification of MRS data with use of prior knowledge. J Magn 
Reson. 1997;129(1):35-43. 
56. Bartha R, Drost DJ, Williamson PC. Factors affecting the quantification of short 
echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR 
Biomed. 1999;12(4):205-16. 
57. Bartha R, Drost DJ, Menon RS, Williamson PC. Comparison of the quantification 
precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magn 
Reson Med. 2000; 44 (2):185-92. 
58. Kauppinen RA, Kokko H, Williams SR. Detection of mobile proteins by proton 
nuclear magnetic resonance spectroscopy in the guinea pig brain ex vivo and their 
partial purification. J Neurochem. 1992;58(3):967-74. 
59. Behar KL, Ogino T. Characterization of macromolecule resonances in the 1H NMR 
spectrum of rat brain. Magn Reson Med. 1993;30(1):38-44. 
60. Théberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, 
Northcott S, Menon RS, Neufeld RW, Rajakumar N, Pavlosky W, Densmore M, 
Schaefer B, Williamson PC. Longitudinal grey-matter and glutamatergic losses in 
first-episode schizophrenia. Br J Psychiatry. 2007;191:325-34. 
61. Stanley JA, Drost DJ, Williamson PC, Thompson RT. The use of a priori knowledge 
to quantify short echo in vivo 1H MR spectra. Magn Reson Med. 1995;34(1):17-24. 
62. Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage. 
2000; 11 (6 Pt 1): 805-21. 
63. Ashburner J, Friston KJ. Why voxel-based morphometry should be used. 
Neuroimage. 2001; 14: 1238-43. 
64. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al. Glutamate and 
glutamine measured with 4.0 T proton MRS in never-treated patients with 
schizophrenia and healthy volunteers. Am J Psychiatry. 2002;159:1944-6. 
65. Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, Lythgoe DJ, O'Gorman RL, 
Barker GJ, McGuire PK; OASIS. Glutamate dysfunction in people with prodromal 
symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry. 
2009;66(6):533-9. 
66. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of 
glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J 
Psychiatry. 2004;161(6):1116-8. 
34 
 
67. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO, 
Kaprio J, Lönnqvist J, O'Neill J, Cannon TD. Proton MRS in twin pairs discordant 
for schizophrenia. Mol Psychiatry. 2010;15(3):308-18. 
68. Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, Nakataki 
M, Ueno S, Harada M, Ohmori T. Metabolite changes and gender differences in 
schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). 
Schizophr Res. 2009;108(1-3):69-77. 
69. van Elst LT, Valerius G, Büchert M, Thiel T, Rüsch N, Bubl E, Hennig J, Ebert D, 
Olbrich HM. Increased prefrontal and hippocampal glutamate concentration in 
schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol 
Psychiatry. 2005;58(9):724-30. 
70. Théberge J, Al-Semaan, Williamson PC, Menon RS, Neufeld RWJ, Schaefer B et al. 
Glutamate and glutamine in the anterior cingulate and thalamus of medicated 
patients with chronic schizophrenia and healthy comparison subjects measured with 
4.0-T proton MRS. Am J Psychiatry. 2003;160:2231-3.  
71. Rothman DL, Behar KL, Hyder F, Shulman RG. In vivo NMR studies of the 
glutamate neurotransmitter flux and neuroenergetics: implications for brain function. 
Annu Rev Physiol. 2003;65:401-27. 
72. Rothman DL, Novotny EJ, Shulman GI, Howseman AM, Petroff OA, Mason G, 
Nixon T, Hanstock CC, Prichard JW, Shulman RG. 1H-[13C] NMR measurements 
of [4-13C]glutamate turnover in human brain. Proc Natl Acad Sci U S A. 
1992;89(20):9603-6. 
73. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, 
Allen M. Alterations in brain high-energy phosphate and membrane phospholipid 
metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal 
prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance 
spectroscopy. Arch Gen Psychiatry. 1991;48(6):563-8. 
74. Fukuzako H, Fukuzako T, Hashiguchi T, Kodama S, Takigawa M, Fujimoto T. 
Changes in levels of phosphorus metabolites in temporal lobes of drug-naive 
schizophrenic patients. Am J Psychiatry. 1999;156(8):1205-8. 
75. Volz HR, Riehemann S, Maurer I, Smesny S, Sommer M, Rzanny R, Holstein W, 
Czekalla J, Sauer H. Reduced phosphodiesters and high-energy phosphates in the 
frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging 
study. Biol Psychiatry. 2000;47(11):954-61. 
76. Shioiri T, Kato T, Inubushi T, Murashita J, Takahashi S. Correlations of 
phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy 
in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res. 
1994;55(4):223-35. 
35 
 
77. Yacubian J, de Castro CC, Ometto M, Barbosa E, de Camargo CP, Tavares H, Cerri 
GG, Gattaz WF. 31P-spectroscopy of frontal lobe in schizophrenia: alterations in 
phospholipid and high-energy phosphate metabolism. Schizophr Res. 2002;58(2-
3):117-22. 
78. Miller J, Williamson P, Jensen JE, Manchanda R, Menon R, Neufeld R, Rajakumar 
N, Pavlosky W, Densmore M, Schaefer B, Drost DJ. Longitudinal 4.0 Tesla (31)P 
magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus 
in first episode schizophrenia. Psychiatry Res. 2009;173(2):155-7. 
36 
 
Chapter 2  
2 Gray matter and social functioning correlates of 
glutamatergic metabolite loss in schizophrenia1 
2.1 Introduction 
The majority of structural neuroimaging studies in schizophrenia have found progressive 
changes such as gray matter loss in subcortical regions.1 There has been considerable 
controversy about what causes the progressive changes. Possible explanations include the 
effects of medication,2 reduced neuropil3 and excitotoxicity induced by N-methyl-D-
aspartate glutamate receptor dysfunction.4 One of the proposed methods to investigate the 
relative contribution of these factors is to combine volumetric analyses with functional 
and neurochemical studies.1 Proton magnetic resonance spectroscopy (1H MRS) at high 
field strengths allows examination of some aspects of excitotoxic processes by the 
quantification of both glutamate and its precursor glutamine in a small volume of interest. 
Very few studies have correlated longitudinal volumetric and neurochemical 
measurements in schizophrenia. 
We previously reported elevated glutamine levels in the left anterior cingulate and left 
thalamus in never-treated first episode schizophrenia5 and decreased levels of glutamate 
and glutamine in the left anterior cingulate of chronically-ill patients,6,7 which  supports 
the possibility of an excitotoxic process. However, these illness phase-related changes 
may be confounded by age and medication effects. More recently, our group examined 
longitudinal changes in glutamatergic metabolites and gray matter in first episode 
schizophrenia over 30 months.8 Within the patient group, decreased thalamic glutamine 
was found at 30 months compared to the baseline. Furthermore, a striking loss of gray 
matter in widespread cortical regions such as dorsolateral prefrontal cortex and temporal 
regions was found over 30 months in these patients. Gray matter loss in the superior 
                                                 
1
 A version of this chapter has been accepted for publication in British Journal of Psychiatry (January, 
2011) 
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temporal gyrus was significantly correlated with the loss of thalamic glutamine. The 
correlation between gray matter and glutamine loss could indicate a degenerative process 
but the study was limited by a relatively short follow-up period. If there is a degenerative 
process in schizophrenia, it likely persists for several years.  
The purpose of this study was to extend our glutamatergic and volumetric assessments to 
seven years in first episode patients studied before treatment and after stabilization with 
antipsychotics. We hypothesized that if there is a degenerative process in schizophrenia 
patients, we would see a loss in not only glutamine but also glutamate and N-
acetylaspartate (NAA), a marker of neuronal integrity9 in the anterior cingulate and the 
thalamus. The glutamate-glutamine cycle accounts for 80-100% of total glutamate 
trafficking in the brain.10 Thus glutamine may be an indicator of glutamatergic 
signalling11 while loss of glutamate, glutamine, and NAA may suggest loss of synaptic 
neuropil. We further hypothesized that the changes in these metabolites would correlate 
with loss of gray matter, particularly in regions which might be expected to be involved 
in schizophrenia such as the frontal and the temporal regions. If these changes in 
glutamatergic metabolites reflect meaningful functional brain changes, we hypothesized 
that we would see a correlation between changes in these metabolites and measurements 
of social functioning despite treatment with medication. 
 
2.2 Method 
2.2.1 Participants 
Seventeen patients diagnosed with schizophrenia participated in this study. The diagnosis 
was established with the Structured Clinical Interview for DSM-IV12 by a psychiatrist 
(P.W.). Ten of the patients were classified as paranoid type and seven patients were 
classified as undifferentiated subtype. Patients were scanned three times: at their first 
assessment in a never-treated state (NT), at 10 months, and at 80 months after their initial 
examination. The MRS data at NT and 10 months from fourteen schizophrenia patients 
have been reported in our previous study.8 Demographic information on participants is 
shown in Table 2-1. Education levels, handedness and length of illness were rated as in 
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our previous study.8 Symptoms were evaluated with the Scale for the Assessment of the 
Negative Symptoms (SANS)13 and the Scale for the Assessment of the Positive 
Symptoms (SAPS).14 Social functioning was evaluated with the Life Skills Profile rating 
scale (LSPRS),15 composed of 39 items with a four-point response scale. This 
questionnaire was completed by a family member living with each patient or a 
caseworker through a phone interview within a few weeks after their latest assessment. 
Seventeen matched healthy volunteers were recruited for the original study with an 
advertisement distributed in London, Ontario. The controls were of comparable age, 
gender, handedness, education level and parental education level. Healthy volunteers 
were scanned twice (Con1, Con2); the mean interval between the two assessments was 
approximately 43 months. Unfortunately, scanner replacement precluded longer follow-
up in the control group. Subjects having a history of alcohol abuse and/or drug abuse in 
the two years before the scan or head injuries were excluded. Nine healthy volunteers 
participated in our previous study.8 The demographic data is displayed in Table 2-1. All 
participants provided written informed consent according to the guidelines of the Review 
Board for the Health Sciences Research Involving Human Subjects at the University of 
Western Ontario. 
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Table 2-1: Participants’ demographic information and data availability 
   Groupsa   
 NT 10 months 80 months Con1 Con2 
 (n = 17) (n = 17) (n = 17) (n = 17) (n = 17) 
Age, mean (s.d.), years 25(7) 25(8) 32(9) 29(10) 32(10) 
Genderb 14M/3F 14M/3F 14M/3F 13M/4F 13M/4F 
Handednessc 12R/3L/2A 12R/3L/2A 12R/3L/2A 13R/4L 13R/4L 
Educational leveld,  
mean (s.d.)      
Participants 2(1) 2(1) 2(1) 3(1) 3(1) 
Parents 3(1) 3(1) 3(1) 3(1) 3(1) 
Subtypee 10P/7U 10P/7U 10P/7U   
LOI, mean (s.d.), months 22(24) 33(27) 106(43)   
Symptom scale, mean 
(s.d.)      
SANS 44(12) 33(11) 33(12)   
SAPS 35(13) 8(8) 7(9)   
LSPRS, mean (s.d.)   128(18)   
Scan period, mean (s.d.), 
months  9(4) 84(31)  43(14) 
Data availabilityf      
Anterior Cingulate, MRS 15X/2E 14X/1E/2M 16X/1E 17X 17X 
Thalamus, MRS 16X/1E 12X/3E/2M 17X 17X 16X/1E 
VBM 17X 15X/2M 17X 17X 17X 
 
LOI, length of illness; LSPRS, Life Skills Profile rating scale; MRS, magnetic resonance 
spectroscopy; SANS, Scale for the assessment of negative symptoms; SAPS, Scale for 
the Assessment of Positive Symptoms; VBM, voxel-based morphometry. 
a. Groups: schizophrenia patients: NT, never-treated; 10 months, on medication for 
approximately 10 months after their first scan; 80 months, approximately 80 months 
medication after their initial assessment; controls: Con1, healthy volunteers comparable 
age, gender and parental educational level with NT patients; Con2, follow-up scan for the 
healthy volunteers in Con1 group. 
b. M, male; F, female. 
c. R, right-handed; L, left-handed; A, ambidextrous. 
d. 1, grade 10 or below; 2, grade 11-13; 3, college 1-3 years; 4, college 4 years or more. 
e. Subtype: P, paranoid; U, undifferentiated. 
f. Data availability: X, available; E, excluded; M, missing. 
 
Medication information is shown in Table 2-2. Five of the schizophrenia patients had 
received antidepressant and/or benzodiazepines 1-10 days prior to their initial assessment 
but had not taken any antipsychotic medication. Twelve of the patients had not received 
any medication prior to their initial scan. All except one patient had been treated with 
atypical antipsychotics at 10 months assessment. At the 80 months scan time, four of the 
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patients were not taking any medication. Two patients had been treated with typical 
antipsychotics while the remainder had been treated with atypical antipsychotics. For the 
patients on antipsychotic treatment, chlorpromazine equivalent doses were calculated in 
our previous study.8 In addition to the medication listed in Table 2-2, three patients had 
been prescribed the following treatment: metformin in one tablet for diabetes, salbutamol 
for asthma or tylenol for pain relief. None of the healthy volunteers, except one 
participant who had taken a multivitamin daily, took any medication or supplements 24 
hours prior to the date of scan.  
Table 2-2: Medication: daily dosage 
  
NT 
(n=17)  
10 months 
(n=17)  
80 months 
(n=17) 
 n 
Mean dosage, 
mg (s.d.) n 
Mean dosage, 
mg (s.d.) n 
Mean dosage, 
mg (s.d.) 
No medication 12  1  4  
Antipsychotics       
Haloperidol   1 1 2 1.3 (0.4) 
Zuclopenthixol     1 6.4 
Risperidone   5 3.7 (2.1) 3 3.3 (2.1) 
Olanzapine   3 7.5 (2.5) 3 26.7 (5.8) 
Quetiapine   3 300 (100) 3 317 (275) 
Ziprasidone   2 100 (84.9)   
Clozapine     2 300 (141) 
Antidepressants       
Paroxetine 1 30b     
Citalopram 2 20 (0)b     
Sertraline   1 50   
Bupropion     1 100 
Benzodiazepines       
Clonazepam 1 4b 3 0.8 (0.3) 1 0.5 
Lorazepam 3 2 (1.7)b   1 0.5 
Zopiclone 1 7.5b     
Benztropine   1 3 2 1.5 (0.7) 
CPZ eqa, mg/day    196 (146)  282 (285) 
 
NT, never-treated schizophrenia patients. 
a. Chlorpromazine equivalent dose. 
b. Taken 1-10 days prior to the scan. 
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2.2.2 Imaging and spectroscopy 
Data were acquired with a 4.0 Tesla whole body MR scanner located at the Centre for 
Functional and Metabolic Mapping of the Robarts Research Institute, London, Ontario, 
Canada. A circularly polarized transmit/receive head coil was used. The MR system was 
monitored by an MR technician, who performed weekly quality control with using the 
phantom and with the echo planner imaging sequence. All data acquisition and 
quantification procedures were performed as described in our previous study8: Imaging, 
voxel positioning (left anterior cingulate and left thalamus (see Figure 2-1)), voxel size 
(1.5 cm3), shimming, spectroscopy (STEAM sequence, echo time = 20 ms, mixing 
time = 30 ms, repetition time = 2000 ms, dwell time = 500 µs), pre-processing, exclusion 
criteria of MR spectrum, spectral fitting and metabolite quantification. Only metabolites 
with a group coefficient of variation ((group standard deviation / group mean) × 100%) 
less than 75% are reported: NAA, glutamate (Glu), glutamine (Gln), choline (Cho), total 
creatine (tCr), myo-inositol (Myo) in the anterior cingulate and the thalamus; taurine 
(Tau) and scyllo-inositol (Syl) in the thalamus only. The “total glutamatergic 
metabolites” (tGL) refers to a sum of Glu and Gln levels quantified individually. A 
complete description of MRI/MRS methods can be found in Appendix B. 
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Figure 2-1: Voxel localization.  
The white rectangles represent spectroscopy voxels in the left anterior cingulate and 
the left thalamus. Localization was performed with transverse T1-weighted images, 
in which the landmark of each region is seen. A, anterior; L, left; P, posterior; R, 
right.  
 
2.2.3 Statistical Analysis 
All statistical analysis was performed with SPSS version 17.0 for Windows. Analysis of 
variance (ANOVA) with a 2 × 2 split-plot factorial (SPF) design was conducted to 
investigate the data composed of two repeated measurements in two independent groups 
(NT and 80 months v. Con1 and Con2). The threshold was set at a two-tailed alpha of 
0.05 for Glu, Gln, tGL and NAA, conservatively inasmuch as the a priori hypotheses of 
their decrease over 80 months were unidirectional. A similar approach was used with a 
separate analysis entailing the three repeated measures for the patient group; however, the 
SPF design was replaced with a 3-level repeated measures (within-subject only, 
randomized blocks) analysis (i.e. NT v. 10 months v. 80 months). An alpha of 0.05 was 
retained when comparing NT v. 80 months, as used in our previous findings while alpha 
43 
 
of 0.05 / 2 = 0.025 (two-tailed throughout) was applied for the two remaining pair-wise 
comparisons (NT v. 10 months, 10 months v. 80 months). Huynh-Feldt epsilon was used 
to adjust error-term degrees of freedom for repeated measures sphericity violations. 
Regarding the other metabolites for which we did not have a priori hypotheses, a region-
wise multivariate analysis of variance (MANOVA) using a 2 × 2 SPF design was applied 
with an alpha of 0.05; a univariate ANOVA on each metabolite followed a significant 
result of the multivariate level of analysis. Commensurate with our previous procedures,8 
within-subject analyses for the patient group comprised pair-wise MANOVA’s, alpha 
being set at 0.05 / 3 = 0.0167 (to accommodate non-orthogonality of these comparisons) at 
both the multivariate and univariate levels, the latter analyses being contingent on 
multivariate-level significance. 
Correlation analyses were performed between metabolite levels of the schizophrenia 
group and their demographic information, clinical scales (SANS/SAPS), social 
functioning scale (LSPRS, 80 months only), length of illness and chlorpromazine 
equivalent dose with the Pearson product-moment correlation coefficient. Threshold 
alpha was set at 0.001 with the exception of the hypothesized relationship between 
metabolites and LSPRS. 
 
2.2.4 Voxel-based morphometry 
Gray matter volume changes were measured with voxel-based morphometry (VBM)16,17 
on the 3D T1-weighted anatomical images using SPM2 (Wellcome Department of 
Imaging Neuroscience, University College London, UK) after normalization as described 
in the section 1.2.2.3.4 in this thesis or elsewhere.8 The general linear model with t-
statistics was applied for statistical comparisons; unpaired t-tests were used for between-
subject comparisons (Con1 v. NT, Con2 v. 80 months), and paired t-tests were used for 
repeated measures, within-subject comparisons (NT v. 10 months v. 80 months, three-
level; Con1 v. Con2). The threshold for each test within each set of tests was established 
according to a multiple-comparison False Discovery Rate (FDR) corrected alpha of 0.001 
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with the extent threshold (cluster size k = 5). Correlation analysis between gray matter 
changes and two of the metabolites, glutamine and NAA, was performed with a test-wise 
alpha of 0.001.8 
 
2.3 Results 
No significant change in the signal-to-noise ratio was detected in the weekly quality 
control throughout the entire study. A total of 168 MRS data (2 regions × (17 patients × 3 
time points + 17 controls × 2 time points) - 2 missing data at 10 months assessment) were 
collected for this study. Nine of these spectra were excluded due to voluntary or 
involuntary movement such as excessive movement or breathing-related movement 
during the data acquisition. Glutamate and glutamine levels in the anterior cingulate from 
one schizophrenia patient were excluded because the raw data for this participant at 80 
months did not fit a glutamate and glutamine peak in this instance.  Because of the non-
physical values for glutamate and glutamine for this case, they were excluded. However, 
for this individual the other metabolites were well resolved, therefore it was decided to 
include them in the statistical analysis. MRS results are shown in the Figure 2-2 with the 
error bar representing the standard deviation of each group. As indicated in Figures 2-2, 
we were not able to follow-up all subjects for technical and/or clinical reasons. Voxel-
based morphometry data were analyzed from 83 anatomical volumes (17 patients × 3 
time points - 2 missing time points + 17 controls × 2 time points) as shown in Table 2-1. 
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Figure 2-2: Metabolite levels. 
Metabolite levels measured in the left anterior cingulate and the left thalamus from 
healthy volunteers (Con1, Con2) and schizophrenia patients (NT, 10 mo and 80 mo). a, 
NT & 80 mo higher than Con1 & Con2, 2×2 SPF analysis in group effect; b, Significant 
reduction from Con1 to Con2 in two-tailed paired t-test; c, 2×2 SPF analysis in 
group×time interaction; d, Significant reduction from 10 mo to 80 mo in two-tailed 
paired t-test; e, Significantly higher level in NT than in Con1 in two-tailed unpaired t-
test; f, Con2 & 80 mo higher than Con1 & NT, 2×2 SPF analysis in time effect; g, 
Significant reduction from 10 mo to 80 mo in two-tailed paired t-test. Cho, choline; 
Con1, healthy volunteers at the initial assessment; Con2, follow-up examination for the 
healthy volunteers; Gln, glutamine; Glu, glutamate; NAA, N-acetylaspartate; NT, 
never-treated; Myo, myo-inositol; Syl, scyllo-inositol; Tau, taurine; tCr, total creatine; 
tGL, sum of glutamate and glutamine; 10 mo, 10 months assessment; 80 mo, 80 months 
assessment. 
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2.3.1 Between-subject comparison 
A 2 × 2 univariate SPF ANOVA on anterior cingulate glutamine yielded a significant 
group effect only (F = 5.04, d.f. = 1,28, P = 0.033). Note that this analysis was applied to 
30 data sets (13 patients and 17 controls) for which glutamate and glutamine were 
available at both time points. Analyses of NAA, glutamate and tGL levels yielded no 
statistically significant results. Multivariate and univariate tests did not evince significant 
effects for any other metabolite. In the thalamus, the univariate 2 × 2 SPF analysis did not 
reveal any group effect for NAA, glutamate, glutamine and tGL. For comparisons at the 
individual time points, the glutamine level of the NT group was significantly higher than 
that of Con1 group (t = 2.72, d.f. = 1,31, P = 0.011) as presented in Figure 2-2. Neither 
multivariate nor univariate tests revealed significant group effects in the other 
metabolites. 
No significant gray matter difference between groups was observed at each time point at 
the FDR alpha of 0.001. Gray matter differences were only seen at an uncorrected alpha 
of 0.001; Con1 gray matter volume was greater than in the NT group in the left thalamus 
(x y z, -20 -24 10, pulvinar, t = 3.71, d.f. = 1,32), Con2 gray matter volume was greater 
than the 80 month group in the left sub-lobar (x y z, -16 28 0, caudate body, t = 4.02, 
d.f. = 1,32) and left superior temporal gyrus (x y z, -66 -8 2, BA 22, t = 3.87, d.f. = 1,32). 
 
2.3.2 Within-subject comparison (three-level) 
Region-wise univariate three-level repeated measures analyses yielded no significant 
findings for NAA, glutamate, glutamine and tGL. Multivariate repeated measures in the 
other metabolites did not yield statistical significance in either the anterior cingulate 
(P = 0.083) or the thalamus (P = 0.034 > 0.0167).  
Among the schizophrenia patients, gray matter in the left anterior cingulate (x y z, -1 53 
2, BA 24 and 32, t = 6.08, d.f. = 1,28) and the left thalamus (x y z, -12 -2 -2, t = 4.52, 
d.f. = 1,28) significantly diminished from the never-treated to 80 months assessment. 
Figure 2-3 represents gray matter loss over 80 months. Significant decrease occurred with 
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respect to the cross-sectional images of the T1-weighted template, centred at the left 
thalamus. Significant loss was also observed in the frontal (BA 4, 10, 45 and 46), 
temporal (BA 21), parietal (BA 7), occipital (BA 18 and 30), limbic lobes (BA 24 and 
30) and sub-lobar (putamen) regions. Significant gray matter loss from 10 months to 
80 months assessment was seen in the frontal lobe (BA 4, 6 and 9). All coordinates are 
listed in Table 2-3. No gray matter loss was observed in 10 months as compared to NT.  
  
 
Figure 2-3: Gray matter loss in schizophrenia over 80 months. 
Gray matter loss from never-treated state to 80 months assessment in schizophrenia 
patients with 3-level repeated measures (false discovery rate corrected P < 0.001). 
Significant reductions represented as shaded region are super imposed on to the 
cross-sectional T1-weighted template images. The bar at the bottom right represents 
the t-value. The cursor in the images was placed in the left thalamus (x y z, -12 -2 -2, 
MNI coordinate). This area showing the significant gray matter loss was indicated 
in the white line. 
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Table 2-3: Voxel-based morphometry: significant gray matter loss with the 3-level 
repeated measures in schizophrenia patients 
x y z R / L Lobe Gyrus BA/sub-
structure 
Cluster 
ka 
Voxel 
t 
   
NT  > 80 mo  (k=5, corrected   p <0.001, d.f. =1,28) 
 
58 26 24 R Frontal Inferior frontal 45 61942 10.86 
54 30 32 R Frontal Middle frontal 46 61942 10.78 
-26 62 4 L Frontal Superior frontal 10 61 4.69 
-50 -14 60 L Frontal Precentral 4 61942 10.86 
-56 -4 -24 L Temporal Middle temporal 21 146 4.79 
-12 -62 36 L Parietal Precuneus 7 991 6.11 
18 -62 30 R Occipital Precuneus 30 873 5.65 
-12 -86 22 L Occipital Cuneus 18 32 4.74 
14 -2 34 R Limbic Cingulate 24 1281 6.14 
16 10 32 R Limbic Cingulate 24 1281 5.40 
-18 -60 16 L Limbic Posterior cingulate 30 991 5.43 
22 -56 14 R Limbic Posterior cingulate 30 873 5.35 
-1 53 2 L Limbic Anterior cingulate 24, 32 61492 6.08 
12 54 10 R Limbic Anterior cingulate 24, 32 64492 6.89 
18 6 2 R Sub-lobar Lentiform Putamen 275 5.42 
-12 -2 -2 L Sub-lobar Thalamus Ventral 
anterior 49 4.52 
  
10 mo  > 80 mo      (k=5, corrected   p <0.001, d.f. =1,28) 
 
28 50 40 R Frontal Superior frontal 9 17 6.27 
-46 6 58 L Frontal Middle frontal 6 5 6.10 
50 -14 62 R Frontal Precentral 4 14 5.94 
 
(k=5, FDR corrected P<0.001, d.f.=1,28) 
NT, Never-treated; 10 mo, 10 months assessment; 80 mo, 80 months assessment; BA, 
Brodmann area; FDR, False discovery rate; L, left; R, right. 
a. Cluster size (voxels). 
 
2.3.3 Within-subject comparison (two-level)  
Within the univariate 2 × 2 SPF layout, no significant time effect or group × time 
interaction was found in NAA, glutamate, glutamine and tGL in the anterior cingulate. In 
a paired comparison, a trend toward decreased in NAA level from 10 months to 80 
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months was found (t = 2.44, d.f. = 1,12, P = 0.031 > 0.025). The MANOVA on the 
remaining metabolites yielded no statistically significant results. A significant univariate 
group × time interaction was found for myo-inositol (F = 5.01, d.f. = 1,29, P = 0.033), 
resulting from a significant decrease over time in controls (t = 2.51, d.f. = 1,16, P = 0.023). 
In the absence of statistical significance at the multivariate level of analysis, like the non-
significant univariate-analysis trend, above, this local result should be considered with 
caution. It nevertheless is reported for possible future consideration.  
Thalamic NAA, glutamate, glutamine and tGL did not show significant effects with 
respect to either time or group × time sources in the univariate 2 × 2 SPF analysis. There 
was a trend toward a decreased glutamine level at 80 months compared to the NT 
measure (t = 1.82, d.f. = 1,15, P = 0.089) while tGL significantly decreased from NT to 80 
months (t = 2.20, d.f. = 1,15, P = 0.044). An example of glutamate and glutamine 
components as well as the fit spectra is presented in Appendix C. Thalamic NAA of the 
schizophrenia group at 80 months significantly decreased from measured levels at 10 
months (t = 2.97, d.f. = 1,11, P = 0.013). The 2 × 2 SPF MANOVA revealed a significant 
time effect in the remaining metabolites (F = 2.84, d.f. = 5,26, P = 0.035). The significant 
multivariate effect was paralleled by a significant univariate time effect for choline 
(F = 4.19, d.f. = 1,30, P = 0.049). There was a trend to increasing choline level at 80 
months compared to NT (t = 1.87, d.f. = 1,15, P = 0.080) but no significant change was 
observed between Con1 and Con2. No significant gray matter loss was found in controls 
between their two scans (Con1 v. Con2). 
 
2.3.4 Correlations 
Correlation between gray matter reduction and loss of thalamic glutamine over 80 months 
was found in the ventral regions such as the right temporal pole (x y z, 16 14 -34, BA 38, 
r = 0.884, P < 0.001), presented in Figure 2-4. The detailed area is listed in Table 2-4. 
NAA reduction over 80 months in the left anterior cingulate correlated with the gray 
matter loss in the posterior regions, listed in Table 2-5.18 Figure 2-5 represents the 
correlation between NAA loss and gray matter reduction in the right inferior parietal 
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lobule (x y z, 62 40 28, BA 40, r = 0.841, P < 0.001). The correlation between the losses 
of gray matter and either glutamine in the anterior cingulate, NAA in the thalamus, or 
tGL in both regions did not reach the P < 0.001 level. Among the changes in metabolites, 
the losses in NAA and tGL levels from 10 months to 80 months tended to be positively 
correlated in the anterior cingulate (r = 0.625, P = 0.025, N = 13).  
 
 
Figure 2-4: Correlation between gray matter loss and glutamine reduction. 
Gray matter loss in the right temporal pole (x y z, 16 14 -34, BA 38) was 
significantly correlated with the reduction of thalamic glutamine from never-treated 
to 80 months assessment in schizophrenia. 
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Table 2-4: Voxel-based morphometry: positive correlation between gray matter loss 
and glutamine loss in the left thalamus from NT to 80 months 
x y z R / L Lobe Gyrus BA/sub-
structure Voxel k
a Voxel 
t 
-10 66 -12 L Frontal Superior frontal 11 493 5.96 
6 68 -14 R Frontal Superior frontal 11 493 5.11 
42 34 -4 R Frontal Middle frontal 47 199 5.35 
-44 34 -4 L Frontal Middle frontal 47 11 4.26 
30 32 -2 R Frontal Inferior frontal 47 199 5.06 
-14 16 -14 L Frontal Subcallosal 47 51 4.62 
16 14 -34 R Temporal Superior temporal 38 529 7.09 
-70 -34 -18 L Temporal Middle temporal 21 676 4.97 
40 -34 0 R Temporal Sub gyral - 5 4.01 
-30 -64 34 R Parietal Angular 39 13 4.08 
-12 6 -34 L Limbic Uncus 28 370 5.07 
 
(k=5, uncorrected P<0.001, d.f.=1,14) 
NT, Never-treated patients; BA, Brodmann area; L, left; R, right. 
a. Cluster size (number of voxels).  
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Figure 2-5: Correlation between gray matter loss and NAA. 
Gray matter loss in the right inferior parietal lobule (x y z, 62 40 28, BA 40) was 
significantly correlated with the reduction of NAA in the left anterior cingulate from 
never-treated to 80 months assessment in schizophrenia. 
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Table 2-5: Voxel-based morphometry: positive correlation between gray matter loss 
and NAA loss in the left anterior cingulate from NT to 80 months 
x y z R / L Lobe Gyrus BA/sub-
structure Voxel k
a Voxel 
t 
-32 22 58 L Frontal Superior frontal 8 7 4.52 
56 8 34 R Frontal Inferior frontal 9 287 7.15 
56 42 4 R Frontal Inferior frontal 46 148 6.14 
62 52 2 R Frontal Inferior frontal 46 148 4.56 
36 16 60 R Frontal Middle frontal 6 27 4.55 
56 -8 46 R Frontal Precentral 4 287 5.58 
-44 -64 54 L Parietal Superior parietal 7 1720 8.48 
-30 -56 68 L Parietal Superior parietal 7 1720 7.87 
16 -74 62 R Parietal Superior parietal 7 752 5.65 
54 -40 52 R Parietal Inferior parietal 40 142 6.86 
62 -40 28 R Parietal Inferior parietal 40 122 5.39 
54 -48 50 R Parietal Inferior parietal 40 142 4.95 
66 -36 38 R Parietal Inferior parietal 40 122 4.33 
46 -68 46 R Parietal Inferior parietal 40 5 4.13 
-50 -74 -34 L Parietal Angular 39 1720 7.24 
16 -58 74 R Parietal Postcentral 7 752 7.47 
56 -16 48 R Parietal Postcentral 3 287 5.09 
-10 -68 40 L Parietal Precuneus 7 30 5.05 
-18 -66 26 L Parietal Precuneus 7 30 4.57 
-10 -74 48 L Parietal Precuneus 7 30 4.31 
-12 -62 22 L Parietal Precuneus 31 30 3.96 
22 -62 22 R Occipital Precuneus 31 285 6.55 
12 -62 26 R Occipital Precuneus 31 285 4395 
-18 84 -2 L Occipital Lingual 17 230 6.04 
28 -66 0 R Occipital Lingual 19 285 5.47 
20 -96 14 R Occipital Cuneus 18 14 4.76 
 
(k=5, uncorrected P<0.001, d.f.=1,12) 
NT, Never-treated patients; BA, Brodmann area; L, left; R, right. 
a. Cluster size (number of voxels). 
 
No correlation between loss of thalamic glutamine level and gray matter reduction was 
found between two measurements in controls. The only significant correlation between 
anterior cingulate NAA reduction with gray matter loss in controls was found in a small 
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cluster (voxel k = 5) in the middle frontal gyrus (x y z, 28 -14 64, BA 6, r = 0.736, 
P < 0.001).  
LSPRS evaluated at 80 months was negatively correlated with the loss of thalamic tGL 
from NT to 80 months (r = 0.694, P = 0.003) (Figure 2-6). Significant correlation between 
chlorpromazine equivalent dose at 80 months assessment and gray matter loss from 
never-treated to 80 months was found in bilateral sub-gyral (x y z, -50 -44 -12, BA 37, 
r = 0.710 ; x y z, 48 -42 -8, BA 37, r = 0.704  ) in the temporal lobe at P < 0.001 level. No 
other correlations were found in the other metabolite levels with SANS/SAPS scores, 
length of illness, the LSPRS and chlorpromazine equivalent dosage. 
 
 
Figure 2-6: Negative correlation between LSP and tGL loss 
Life skills profile rating scale at 80 months assessment was negatively correlated 
with the total glutamatergic metabolites (tGL) in the thalamus from never-treated 
to 80 months assessment in schizophrenia 
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2.4 Discussion 
2.4.1 Neurochemical Alterations 
Glutamine levels in never-treated patients were significantly higher than controls in the 
left thalamus in keeping with the previous reports5,8 while levels in the anterior cingulate 
were not significantly different between groups possibly due to higher standard 
deviations in the control samples. No differences were seen between never-treated 
patients and patients stabilized on medications suggesting that neuroleptic medication did 
not affect glutamatergic metabolite levels.  
Although we did not see a significant reduction in thalamic glutamine level over 80 
months in schizophrenia, there was a significant decrease in the total glutamatergic 
metabolites (tGL), suggesting glutamatergic metabolism continues to decline with disease 
progression. This glutamatergic loss in the thalamus could also suggest a loss of neuropil 
in schizophrenia. This observation is consistent with the suggestion that excitotoxicity 
occurs primarily in the early stages of illness.19 However it is also possible that 
glutamatergic findings could be accounted for by alterations in the activity and density of 
glutamate dehydrogenase and glutamine synthetase which have been reported to be 
anomalous in post-mortem schizophrenic brain extracts.20 The thalamic tGL reduction 
was inversely correlated with the LSPRS, suggesting a connection between glutamatergic 
neurophysiological changes and the impairment of social behavior. It is of note that this 
correlation was found despite treatment with antipsychotic medications. Therefore, this 
finding indicates that the change in glutamatergic metabolites may be a potential 
indicator of severity in schizophrenia in terms of social functioning.  
Indeed, Tibbo et al.21 reported a correlation between Glu/Gln ratio in the frontal cortex in 
adolescents at high-risk for schizophrenia and Global Assessment of Functioning Scale, 
suggesting the glutamatergic changes are a candidate marker in the early stage of 
schizophrenia. Wood et al.22 reported a strong correlation between NAA/Cr ratio in the 
middle frontal gyrus in the patients with psychosis and the Social Functional Assessment 
Scale at 18 months follow-up. Although there are several differences such as the 
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metabolite and its region compared to this study, they also suggest a connection between 
metabolites and functional outcome. 
In addition to the glutamatergic findings, a trend in the reduction in the levels of NAA 
was found in the left anterior cingulate (P = 0.031 > 0.025) and a reduction was found the 
left thalamus (P = 0.013) between the 10 months stabilized on medication and the 80 
months assessment. These NAA deficits were not found to differ in a 30 month study.8 
As NAA levels are generally thought to reflect neuronal integrity, this decline would be 
consistent with decreasing glutamatergic metabolite levels and possibly a loss of neuropil 
or limited apoptosis. Indeed, NAA and tGL reductions from 10 months to 80 months 
assessment tended to be positively correlated in the anterior cingulate suggesting that 
both metabolites may be related to neuropil loss. However, medication effects are also a 
possibility as NAA levels in never-treated patients were not statistically different from 
the same patients at 80 months follow-up. 
No differences in glutamate, glutamine, tGL and NAA were seen in controls between 
baseline and follow-up scans. Those findings were consistent with the measurement at 30 
months.8 However, controls in this study were not followed as long as patients due to 
decommissioning of the MRI system. This study had been running over 12 years on the 
same MRI scanner. Compared at the latest assessment, glutamate and glutamine levels in 
schizophrenia were not significantly different from those in controls. Decreased levels of 
both metabolites have been reported in the anterior cingulate in chronic patients who had 
been ill in excess of 20 years.6 The lack of differences at 80 months between controls and 
patients implies that metabolite levels change more slowly over a considerable length of 
time.  
 
2.4.2 Volumetric Alterations 
There was no significant difference between never-treated schizophrenia patients and 
controls with FDR corrected P < 0.001 level while some gray matter losses were observed 
with the uncorrected P < 0.001 level in the thalamus, where significantly higher glutamine 
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level was found in schizophrenia. However, these differences were not to the extent 
expected if schizophrenic symptoms were due to a programmed loss of neuropil.3  
Significant gray matter loss in schizophrenia patients over 80 months was observed in 
many brain regions including the anterior cingulate and the thalamus. This result suggests 
that it takes 7 years until gray matter losses are observable in many regions. Indeed, no 
reduction in the anterior cingulate and the thalamus was found during the 30 months 
assessment in our previous report.8 A gray matter reduction was also found in the frontal 
lobe in the 80 months compared to never-treated assessment and to the 10 months 
assessment, highlighting the importance of the frontal lobe in schizophrenia. There was 
no significant gray matter loss from never-treated to 10 months assessment, suggesting 
that the acute effects of medication are minimal. Significant correlations between gray 
matter loss over 80 months and chlorpromazine equivalent dose were found only in the 
sub-gyral in temporal lobe bilaterally suggesting that medication is not likely the 
explanation for the widespread gray matter losses seen in these patients.  
There was no significant gray matter loss in controls between the two assessments, 
implying aging effects are minimal. However, the mean scan period of controls was 
around 3.5 years, shorter than the patients’ scan period. No significant gray matter 
difference (FDR corrected P < 0.001) was found in Con2 compared to 80 months. There 
were differences in the left superior temporal gyrus and caudate nucleus, albeit by more 
liberal criteria (uncorrected P < 0.001), but which nevertheless are consistent with both 
our earlier study8 and with another study.23 
 
2.4.3 Correlations between Gray Matter and Metabolite Losses at 
80 months 
The amount of thalamic glutamine in schizophrenia patients was significantly correlated 
with gray matter volume in the middle and inferior frontal gyrus as well as in the 
temporal pole. A similar correlation between thalamic glutamate and gray matter loss in 
these regions was reported in subjects at risk of developing schizophrenia.24 Several 
prefrontal regions and temporal pole are associated with social and emotional processing 
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which may be deficient in schizophrenia patients.25,26 As discussed in the previous 
section, social functioning on the LSPRS was negatively correlated with tGL loss in the 
thalamus in patients, suggesting this correlation is mediated in part by these widespread 
structural changes. No correlations were found between losses of thalamic glutamine and 
gray matter in controls, suggesting that aging did not play a significant role. 
The reduction of NAA in the anterior cingulate was significantly correlated with the gray 
matter loss over 80 months in posterior-parietal areas. This area is associated with 
attention which many investigators have found to be altered in schizophrenia.27 These 
regions are also interconnected and form part of the default network associated with self-
monitoring. Aberrant connectivity between the anterior portions of this network and other 
regions in schizophrenia patients has been reported by our group and others.28-30 
Localized changes in these networks reflected by metabolic measures could lead to 
difficulties in self-monitoring which may underlie many symptoms of schizophrenia.29 In 
contrast to multiple locations in schizophrenia, reduction in the anterior cingulate NAA 
levels in controls was only correlated with gray matter loss in the motor area. This cluster 
size was equal to the extent threshold, suggesting minimal correlation between neuronal 
integrity and neuropil in normal aging. 
 
2.4.4 Excitotoxicity or Plasticity 
Although metabolite reductions, gray matter loss and their correlations over 80 months 
may suggest a neurodegenerative process in schizophrenia, there has been a debate about 
whether these anomalies are caused by excitotoxicity or plasticity. In contrast to our 
previous report,8 here, a loss of glutamatergic metabolites was observed in the thalamus 
concurrently to gray matter loss within the spectroscopic voxels (i.e. the anterior 
cingulate and the thalamus). If there is an excitotoxic process in schizophrenia, 
significant loss of gray matter in the thalamus might be expected in patients compared to 
controls at their initial assessment. However, there was no significant difference between 
these groups, suggesting the glutamatergic metabolite changes may be more sensitive to 
early changes not associated with gray matter loss.  
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Thalamic glutamatergic neurons are interconnected to all the cortical regions which were 
associated with gray matter loss in the schizophrenia patients. They also form part of the 
basal ganglia-thalamocortical neuronal circuit implicated in the pathophysiology of 
schizophrenia.31 Thus glutamatergic changes in the thalamus could be associated with 
glutamatergic changes throughout the cortex. Cortical gray matter losses could be 
accounted for by excitotoxicity into these regions. Increased membrane breakdown has 
been reported in first episode schizophrenia patients in a phosphorus MRS study.32 The 
decrease in NAA and decrease in gray matter over time in the anterior cingulate in this 
study would be compatible with this explanation. The trend to increased thalamic choline 
levels in patients at 80 months may also suggest excitotoxicity as these levels reflect 
mostly membrane metabolites. A positive correlation between choline and the duration of 
untreated psychosis has been found in first episode patients.33 However, it is possible that 
these circuits are simply being down-regulated leading to plastic changes in gray matter 
and the metabolic changes. 
 
2.4.5 Limitations 
Although the absence of differences in metabolites and gray matter between the never-
treated and 10 month assessments in patients argues against medication effects, the 
effects of exposure to medication can never completely be eliminated due to ethical 
considerations. Another limitation may be the stability of the MR scanner associated with 
the inevitable hardware replacements and/or upgrades that occur during such a long-term 
period but the stability of our MR system was carefully monitored through routine 
weekly quality control. We did not regularly calibrate the metabolite quantification. 
However, the metabolite levels were quantified with the internal water reference which 
minimizes short- and long-term scanner drift. Due to scanner replacement, we were 
unable to follow controls as long as patients. Consequently we cannot exclude the 
possibility that controls may have had further NAA losses had we followed them longer. 
The lack of obvious changes in tGL between the two assessments in controls suggest that 
aging alone would be unlikely to account for changes seen in patients at the 80 month 
assessment.  
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Chapter 3  
3 Gray matter vs. metabolite signal to noise ratio 
3.1 Introduction 
Advances in neurochemical and structural imaging have contributed much to the 
understanding of neuropsychiatric diseases such as Alzheimer’s disease and 
schizophrenia.1 Since these illnesses are progressive, they are possibly neurodegenerative 
disorders.2,3 Decreases in N-acetylaspartate (NAA) level, an indicator of neuronal 
integrity and neuropil volume, have been reported in longitudinal studies of both 
conditions.4,5 Glutamate is another possible marker of neurodegeneration because of 
excitotoxicity associated with the excessive release of this neurotransmitter in conditions 
like schizophrenia.6 However, findings are inconsistent in terms of the pattern of brain 
changes. Therefore, it has been suggested that volumetric measurements should be 
combined with metabolite changes.7  
Magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H 
MRS) are used to measure volumetric and neurochemical abnormalities in the human 
brain, respectively. In the past three decades, anomalies in brain tissue and in metabolite 
levels in schizophrenia have been reported with these techniques. Our group found 
increased levels of glutamine in the anterior cingulate and the thalamus in schizophrenia 
patients before treatment compared to a control group using MRS.8 Théberge et al.8 also 
reported correlated losses of thalamic glutamine and gray matter in those patients over a 
30 month period.9 We recently found longitudinal decreases in the levels of NAA and 
total glutamatergic metabolites in the thalamus in the same schizophrenia patients after 
80 months.10  
It was unclear if our findings represented actual or apparent decreases in metabolite 
levels due to the gray matter loss in the spectroscopy voxel. These quantified metabolite 
levels were normalized with an arbitrary correction factor, composed of gray matter, 
white matter and cerebrospinal fluid (CSF) percentage in the spectroscopy voxel. 
However, we did not correlate the raw metabolite MR signal with the actual amount of 
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gray matter in the voxel to determine if they were related. If gray matter changes 
correlate highly with glutamatergic metabolite changes then glutamatergic changes may 
reflect a loss of neuropil rather than physiologically-relevant concentration changes in 
this neurotransmitter. We also did not examine the effects of losses in gray matter in the 
voxel on signal-to-noise ratio (SNR) which may have affected the precision of the 
metabolite determination. 
Long term longitudinal studies of neuropsychiatric disorders are becoming increasingly 
common. However, to our knowledge no studies have examined the effects of gray 
matter loss on the precision of measurements of relevant brain metabolites over time. The 
purpose of this study was to examine the effects of gray matter loss on the measurement 
of NAA and glutamatergic metabolites over 80 months in a group of schizophrenic 
patients and controls. We hypothesize that gray matter losses alone would not account for 
longitudinal changes in glutamatergic metabolites but that losses of gray matter may 
affect SNR making it more difficult to detect changes over time. 
 
3.2 Methods 
3.2.1 MR imaging and spectroscopy 
Data were collected from seventeen schizophrenic patients and seventeen comparable 
controls using in vivo proton magnetic resonance spectroscopy. Participant’s 
demographic information, details of the medication, imaging sequence, spectroscopy 
sequence, spectrum fitting, preprocessing and quantification are described in our previous 
studies9,10 and in Chapter 2 of this thesis. Briefly; patients were scanned three times: at 
their first assessment in a never-treated state (NT), at 10 months, and at 80 months after 
their initial examination. Healthy volunteers were scanned twice (Con1, Con2); the mean 
interval between the two assessments was approximately 43 months.  In order to observe 
the influence of the gray matter segments in the spectroscopy voxel, a correction factor 
composed of the tissue percentage was excluded in the quantification procedure. Voxel 
segmentation is described in the following section. Metabolite levels in this study were 
uncorrected values. Only neuron relevant metabolite levels, N-acetylaspartate (NAA) and 
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total glutamatergic metabolites (tGL) are included in the statistical analysis. The SNR of 
water and the metabolites are calculated in the time domain. For the SNR calculation, the 
signal was taken as the water or metabolite signal at time = 0 (which is proportional to 
peak area in the frequency domain). The noise level was defined as the standard deviation 
of the last 32 complex pairs in the time domain.   
  
3.2.2 Voxel segmentation 
Segmentation analyses for the spectroscopy voxel were performed with ANALYZE and 
an in-house software Xstatpack, developed by J Davis. The T1 weighted transverse 
images were reoriented based on the anterior-posterior cingulate plane and reformatted to 
the isotropic resolution (0.78 × 0.78 × 0.78 mm3) using ANALYZE software. After the 
localized spectroscopy voxel was positioned, a quantitative histogram of the signal 
intensity was created in each slice with Xstatpack. Thresholds of tissue types were 
determined with the histogram. Voxel bins that were registered into gray matter, white 
matter or CSF were summed throughout all slices within the spectroscopy voxel 
(15 × 10 × 10 mm3). The gray matter fraction was calculated as the volume of gray matter 
divided by the total volume of the spectroscopy voxel, 1500 mm3.  
 
3.2.3 Statistics 
To probe the interplay between gray matter percentage in the spectroscopy voxel and the 
quantified metabolite levels, analyses of variance were performed with a varying 
continuous independent variable (i.e. gray matter) in each 3-level repeated measures (NT 
vs. 10 months vs. 80 months) and 2 × 2 split plot factorial designs (NT & 80 months vs. 
Con1 & Con2). Predictive Analysis of Software (PASW) only handles a constant 
covariate throughout the measurement periods per subject with analysis of covariance 
(ANCOVA) or Multiple ANCOVA. According to procedures described by Dr. Robert C. 
Gardner,11 in ANOVA a varying continuous variable is taken into account using multiple 
regression analysis. Metabolite levels, SNRs, peak areas and gray matter are all 
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dependent variables in this study. To perform this multiple regression analysis, gray 
matter was selected as a varying independent variable (i.e. covariate). Either metabolite 
level, SNR or peak area was set as a dependent variable. The covariate, gray matter, was 
“centered” (individual value minus the grand mean of gray matter) in each data analysis. 
Centering the gray matter allows the comparison of the intercept, which represents an 
expected dependent variable if gray matter was consistent in a comparison (e.g. NT vs. 
80 months). The use of a covariate allows all subjects to be normalized with respect to a 
confounding variable. Thus, it is statistically possible to control for gray matter values. 
The statistical comparison using the adjusted gray matter values was performed in the left 
thalamus for: NAA level, tGL level, NAA SNR, tGL SNR, NAA peak area and tGL peak 
area. Thresholds for the statistical analyses, 3-level repeated measures and 2 × 2 SPF 
analysis, were described in our previous study (Chapter 2).10  
 
3.3 Results 
Significant findings in the regression analyses described above and the significance from 
our previous study10 are summarized in Table 3-1. The NAA peak area was found to be 
significant with the three-level repeated measures in the original 80 months data 
(F = 5.55, d.f. = 2,22, P = 0.011). However, there was no significance in the NAA peak 
area following the gray matter adjustment (F = 3.65, d.f. = 2,20, P = 0.045 > 0.0167). No 
significance in the three-level repeated measures was found in any other variables in 
either the original data sets or those with the gray matter adjustment.  
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Table 3-1: Statistical significance in the thalamic (a) NAA and (b) tGL levels before 
and after the gray matter adjustment. 
(a) 
Metabolite levels SNR Peak area 
NAA Original ANCOVA Original ANCOVA Original ANCOVA 
3-level RM       
Time 0.071 0.185 0.039 0.125 0.011* 0.045 
NT vs. 10mo 0.776 0.761 0.835 0.746 0.058 0.165 
NT vs. 80mo 0.153 0.262 0.277 0.494 0.980 0.439 
10movs. 80mo 0.013* 0.031 0.028 0.065 0.011* 0.027 
2x2 SPF       
Group 0.878 0.861 0.323 0.294 0.897 0.429 
Time 0.075 0.129 0.128 0.242 0.371 0.823 
Group × Time 0.745 0.546 0.668 0.722 0.352 0.174 
NT vs. Con1 0.692  0.322  0.442  
80mo vs. Con2 0.971  0.473  0.826  
(b)  
Metabolite levels SNR Peak area 
tGL Original ANCOVA Original ANCOVA Original ANCOVA 
3-level RM       
Time 0.442 0.585 0.074 0.190 0.104 0.136 
NT vs. 10mo 0.638 0.864 0.835 0.756 0.188 0.230 
NT vs. 80mo 0.044* 0.970 0.190 0.569 0.733 0.793 
10movs. 80mo 0.267 0.317 0.075 0.136 0.066 0.098 
2x2 SPF       
Group 0.677 0.656 0.300 0.498 0.875 0.844 
Time 0.206 0.865 0.127 0.383 0.148 0.376 
Group × Time 0.132 0.970 0.483 0.939 0.069 0.195 
NT vs. Con1 0.273  0.233  0.228  
80mo vs. Con2 0.724  0.604  0.370  
 
Original, original 80 months study; ANCOVA, analysis of covariance (gray matter as a 
covariate). *P < 0.0167 (Time, 3-level), *P < 0.025 (NT vs. 10mo,  10mo vs. 80mo), 
*P < 0.050 (NT vs. 80mo, comparisons in 2x2 SPF).  
 
Schizophrenia: 10mo, 10months assessment; 80mo, 80 months assessment. NT, never-
treated. Control: Con1, initial scan in healthy volunteers; Con2,  follow-up scan in the 
healthy volunteers. 3-level RM, three-level repeated measures; 2 × 2 SPF,  two-by-two 
split plot factorial design (NT & 80 mo vs. Con1 & Con2).  
NAA, N-acetylaspartate;  SNR, signal-to-noise ratio; tGL, total glutamatergic metabolite 
levels (glutamate + glutamine) 
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There was a trend toward decreasing thalamic NAA metabolite levels following the gray 
matter adjustment between the 10 months and 80 months assessments (F = 6.28, 
d.f. = 1,10, P = 0.031) while a significant decrease was found in this comparison in the 
original study using a two-tailed paired t-test (t = 2.97, d.f. = 1,11, P = 0.013). Regression 
plots at 10 months and 80 months assessment are presented in Figure 3-1. No significant 
change was found in gray matter adjusted thalamic tGL levels from NT to 80 months 
(F < 0.01, d.f. = 1,14, P = 0.970) while those tGL levels were significantly decreased in the 
original 80 months study (t = 2.20, d.f. = 1,15, P = 0.044). Figure 3-2 shows their 
correlation plots at NT and 80 months.  
No significant change in NAA SNR from 10 months to 80 months was found using the 
ANCOVA analysis (F = 4.28, d.f. = 1,10, P = 0.065) while there was a decreased trend in 
the original 80 months study (t = 2.54, d.f. = 1,11, P = 0.028). There were no significant 
changes in tGL SNR from the NT to the 80 months assessment in either the original data 
or those with the gray matter adjustment (Table 3-1).  
The NAA peak area at 80 months was significantly decreased compared to 10 months in 
the original data sets (t = 3.07, d.f. = 1,11, P = 0.011) while there was a trend toward a 
decreasing NAA peak area after the adjustment using the ANCOVA (F = 6.67, d.f. = 1,10, 
P = 0.027 > 0.025). No significant changes were observed in the tGL peak area in any 
comparisons in either the original or the data with the gray matter adjustment. 
There was no significant effect in the 2 × 2 SPF analyses in either the original or the gray 
matter adjusted variables (Table 3-1). 
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Figure 3-1: Thalamic NAA level adjusted by gray matter in the voxel. 
Average NAA level indicates the mean value in the individual measurement period. 
Intercept in a regression equation indicates the NAA level if gray matter does not 
change between (a) 10 months and (b) 80 months. NAA, N-acetylaspartate 
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Figure 3-2: Thalamic tGL level adjusted by gray matter in the voxel. 
Average tGL level indicates the mean value in the individual measurement period. 
Intercept in a regression equation indicates the tGL level if gray matter does not 
change between (a) NT and (b) 80 months. NT, never-treated schizophrenia patient; 
tGL, total glutamatergic metabolites (glutamate + glutamine) 
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3.4 Discussion 
3.4.1 Gray matter effect against NAA and tGL 
While the thalamic NAA level in schizophrenia patients was significantly decreased from 
the 10 months to the 80 months assessment in the original study (P = 0.013), only a trend 
toward a decreasing level was observed in the gray matter adjusted NAA level 
(P = 0.031 > 0.025). This result suggests that gray matter in the spectroscopy voxel affects 
the NAA level but that the influence is minimal because there was only a trend to lower 
levels in this comparison.  
NAA SNR and peak area at 80 months were both lower than those at the 10 months 
assessment, but the significance of those differences became less prominent following the 
gray matter adjustment. The significance of the NAA SNR between 10 and 80 months 
moved from a trend (P = 0.028) to non-significant (P = 0.065), while the significance 
difference in the NAA peak area between 10 and 80 months (P = 0.011) was reduced to 
the level of a trend following the gray matter adjustment (P = 0.027). These results imply 
that gray matter in the spectroscopy voxel might be associated with NAA SNR and peak 
area as well as NAA metabolite level. However, the statistical p-value in ANCOVA 
hovers around the threshold, suggesting the effect of gray matter is subtle because the 
SNR and peak area depend more upon the hardware performance rather than tissue 
composition in the voxel of interest.  
Thalamic tGL level adjusted by gray matter did not significantly decrease from NT to 80 
months (P = 0.970) while in the original study, it was found to be significantly decreased 
(P = 0.044). Unlike NAA level in the thalamus, the statistical significance in the adjusted 
tGL level completely disappeared, suggesting that gray matter loss may be responsible 
for the decreased tGL level from NT to 80 months.  
No significant change in tGL SNR or peak area was found in either the original study or 
the analysis with the gray matter adjustment. The statistical p-value in tGL SNR (NT vs. 
80 months) with the gray matter adjustment (P = 0.569) varied from the tGL level without 
adjustment (P = 0.190), whereas the p-values in the adjusted and non-adjusted tGL peak 
area were quite similar. Consistent statistical significance suggests the tGL peak area was 
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not affected by gray matter. It indicates that noise from the data without water 
suppression was possibly increased due to the gray matter loss in the spectroscopy voxel 
from NT to the 80 months assessment. In fact, different statistical p-values in the tGL 
SNR with and without adjustment suggest that metabolite SNR was affected by gray 
matter loss. This reduction in gray matter might lead to increased magnetic susceptibility 
artifacts, suggesting a structural change.  
 
3.4.2 Physiological or structural change? 
Although both NAA and tGL are neuron relevant metabolites, gray matter changes may 
affect each of these metabolites differently. While NAA levels tended to be reduced after 
the gray matter adjustment (P = 0.031, 10 months vs. 80 months), no significance in the 
adjusted tGL level was found (P = 0.970, NT vs. 80 months). NAA level measured with 
MR spectroscopy is considered to be a marker of neuronal integrity.12 Significantly lower 
NAA levels in schizophrenia patients are often found in the studies of MR spectroscopy 
but this does not necessarily imply that there is a loss of neurons.13 In fact, NAA can be 
affected by medications without apparent loss of neurons.14 Thus NAA is likely a marker 
of neuronal integrity which may be somewhat independent of structural changes 
providing some explanation for the minimal effects of gray matter loss on NAA changes 
over time in this study. 
While NAA level is considered to be associated with neuronal integrity, tGL levels 
composed of glutamate and glutamine may be a reflection of synaptic integrity. 
Glutamate is stored in the vesicle in the axon terminal and is physiologically activated as 
a neurotransmitter in the synaptic cleft, the gap between two neurons.15 Glutamine is 
synthesized after glutamate is taken up from the synapse into glial cells. It then diffuses 
back to the neuron to be used again as a neurotransmitter. Decreased levels of glutamate 
and glutamine measured by MR spectroscopy over time can be related to a physiological 
down-regulation of glutamate signaling or a loss of gray matter due to excitotoxicity, loss 
of neurotrophic factors or a number of other factors.7 In postmortem studies, Selemon et 
al.16 found significantly increased neuronal density in the prefrontal cortex in 
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schizophrenia compared to controls which was interpreted as a loss of neuropil or 
synaptic connections. Our observation of tGL differences over 80 months10 could be 
explained either by a physiological down-regulation or a loss of synaptic gray matter in 
the regions studied. Glutamatergic metabolite levels were normalized to some extent by a 
correction factor in this study. However, the findings in the present study suggest that 
tGL level differences over time in schizophrenic patients disappear when the effects of 
gray matter are more carefully controlled. Thus the present results suggest that 
differences over time in tGL level in schizophrenic patients are more likely to be related 
to loss of neuropil and gray matter than a physiological down-regulation of 
neurotransmitter activity.  
The significance in the metabolite SNRs and peak areas with the gray matter adjustment 
was similar to the analyses without the adjustment. Although statistical p-values in tGL 
SNR were changed, both differences in tGL SNR with and without adjustment were non-
significant. This observation suggests that gray matter loss did not affect the magnetic 
susceptibility making it more difficult to detect metabolite changes. However, the 
metabolite SNR defined in this study depended on the hardware performance on the date 
of the scan. 
 
3.4.3 Implications for excitotoxicity 
It is still unclear whether both tGL level and gray matter were decreased at a similar rate 
or whether the reduction in tGL level was led by gray matter loss. ANOVA with a 
varying continuous variable takes gray matter into account when the statistical 
comparisons in the metabolites are conducted. This method only indicates whether gray 
matter amount is associated with the metabolite level but does not indicate how 
metabolite level might have changed without gray matter loss in our previous 80 months 
study.10 It is possible that there might have been an early physiological increase in 
glutamatergic metabolites leading to excitotoxicity and loss of synapses and gray matter 
which then led to the loss of glutamatergic metabolites. Consequently an early 
74 
 
physiological increase in glutamatergic activity followed by structural changes in 
neuropil cannot be ruled out. 
 
3.4.4 Limitations 
Decreased gray matter fraction is possibly caused by a misplacement of the spectroscopy 
voxel due to an involuntary movement of the subject before and after the voxel 
localization. Subjects were monitored from the superior part of their head during the 
experiment. However, it is difficult to detect a head movement along the Z axis, 
paralleled to the B0 direction and the head rotation in the anterior-posterior direction. For 
instance, if the subject slightly moved to the superior direction before the spectroscopy 
acquisition, the localized voxel would be inferior to what was selected using the T1 
weight images. Therefore, this spectrum would be composed of the MR signals from the 
voxel of interest and from signal outside of the voxel.  
Voxel localization might not be identical between the first and follow-up scans. Although 
the spectroscopy voxel was localized using landmarks in the brain, the localized voxel 
may not be exactly the same as that in the other follow-up scans. Furthermore, the data 
was collected by three operators, which might result in a misplacement of the 
spectroscopy voxel. 
The scan interval in the healthy volunteers was not comparable to that in the 
schizophrenia patients. Gray matter loss in controls might be missed due to the shorter 
follow-up period. Small gray matter changes make it difficult to detect the correlation to 
with the metabolite levels, SNRs and peak areas.  
Gray matter in this study may include white matter. Although the thalamus is mostly 
composed of the gray matter, it also contains some white matter. Since gray matter is 
abundant compared to the white matter, most image pixels are recognized as gray matter 
in terms of the contrast. Metabolite levels are different between gray matter and white 
matter, even though gray matter and white matter are indistinguishable in this image 
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analysis. It may be that the influence of white matter is negligible due to the small 
amount of white matter compared to the amount of gray matter. 
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Chapter 4  
4 The perils of long-term proton magnetic resonance 
spectroscopy studies 
4.1 Introduction 
Neuroimaging techniques are useful in the cross-sectional investigation of abnormalities 
in psychiatric disorders.1 However, long-term observation is essential for the 
understanding of neurodegenerative disorders such as Alzheimer’s disease and 
schizophrenia.2 Magnetic resonance imaging and spectroscopy allow the examination of 
long term structural and neurochemical changes. In a previous study, we examined first 
episode schizophrenia patients before treatment, followed by 10 months and 30 months 
after the medication, using magnetic resonance spectroscopy at 4 Tesla.3  
For a long term study however, the reliability of the data is strongly dependent upon the 
stability of the hardware during the course of the project. Ideally the Signal to Noise 
Ratio (SNR) should be maintained at the same level throughout the project. Despite that, 
because MRI systems are complex clinical systems, there will inevitably be hardware 
upgrades and/or replacements required to maintain the system. The longer the project 
duration, the more likely such difficulties will arise. Our group recently conducted an 80 
month follow-up study using magnetic resonance spectroscopy at 4 Tesla. Data was 
collected from schizophrenia patients over 7 years and anomalies were found in NAA 
and glutamatergic metabolites in schizophrenia patients.4 During the 7 year duration of 
this project, there were several upgrades in the MR system. Consequently, a critical part 
of internal quality control is to ensure that these measured metabolite concentration levels 
are not artificially modified by the changes in the hardware.  
SNR is a good measure to track the hardware stability in a long term project.5 In this 
present study, SNR was measured in the time domain rather than in the frequency 
domain. The advantage of measuring SNR in the time domain is that signal amplitude is 
independent of the linewidth while peak intensity in the frequency domain is significantly 
dependent on the linewidth. Under the same metabolite concentration level, peak area 
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underneath the metabolite spectrum is constant while peak intensity varies with respect to 
the linewidth, determined by T2*. If SNR is measured in the frequency domain, peak 
intensity should be corrected by linewidth before comparing the SNR. Linewidth is 
another good standard to gauge the quality of the spectrum; however it is more affected 
by differences in the head structure of the participants and voxel positioning in the brain, 
and location with respect to isocentre, rather than hardware changes.  
The purposes of this study were: (i) to determine if the SNRs of the MR signals for water, 
NAA and tGL in both the schizophrenia and the control groups were significantly 
correlated with magnet age; (ii) if there are any significant differences in these SNR 
levels throughout the duration of the study, to determine if any hardware modifications 
may be responsible, and if so to simulate comparable SNR levels throughout the 10 year 
period; and (iii) to evaluate the NAA and tGL concentration levels after replacing the 
original data with this simulated data, using the same statistical comparison conducted in 
the 80 month study.4 We hypothesize that the significant differences or changes observed 
in the metabolite levels in an 80 month study would persist when the original data were 
replaced with the SNR adjusted (addition of random noise) data.  
 
4.2 Methods 
4.2.1 Participants, imaging and spectroscopy 
Data were acquired from 17 schizophrenia patients and 17 healthy volunteers, those who 
participated in our previous study.4 Demographic information was exactly the same as 
our previous study (see Chapter 2). Schizophrenia patients were scanned before treatment 
(NT, never-treated) as well as at 10 months and 80 months after their initial assessment. 
Controls were scanned twice (Con1, Con2), and the time period between the two 
assessments was approximately 43 months. All experiments were performed with a 4 
Tesla whole body scanner located at the Functional and Metabolic Mapping Centre at the 
Robarts Research Institute, London, Ontario Canada. All procedures including shimming, 
imaging sequence, voxel localization, spectroscopy sequence (STEAM, echo 
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time = 20 ms, mixing time = 30 ms, repetition time = 2 s, dwell time = 500 µs), pre-
processing, spectral fitting and quantification have been described previously.3,4  
 
4.2.2 SNR, linewidth and magnet age 
Signal-to-noise ratio and raw signal were defined in the time domain. Raw signal was 
defined as the amplitude of the water or metabolite Free Induction Decay (FID), from 
which the recorded signal was decomposed through the fitting procedure introduced in 
this section. Noise was calculated from the standard deviation of the last 32 complex 
points in the time domain in each suppressed and unsuppressed dataset. Water linewidth 
was determined by the fitting procedure and specified as the full width at half maximum 
of a fitted single peak Lorentzian component. To examine the MR system stability, 
correlation analyses were performed versus magnet age for water linewidth, and SNR of 
water, NAA and tGL.  The magnet age was defined with respect to the date of the earliest 
scan (August 27, 1997) in this study. For this discussion we are using ‘magnet age’ to 
define the age of the entire MR system as the magnet was not changed over the 7 years, 
whilst most of the other components were replaced and/or modified during the study (e.g. 
gradients, gradient amplifiers, receiver electronics, RF amplifier, MR console); 
Magnet age [year] = {(Date of scan) – (August 27, 1997)} / 365 days. 
This correlation analysis was performed at each measurement period in each group (e.g. 
NT, Con 1) as well as a correlation combining all the samples in the schizophrenia group 
(NT, 10 months plus 80 months) and similarly for the control group (Con1 plus Con2). 
The latter correlations are not meaningful statistical analyses because each sample is not 
truly independent in terms of subject. Nevertheless, we performed this correlation 
analysis only to detect a significant change in SNR at a particular time period over the 
entire magnet age.  
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4.2.3 Random noise 
Presumably because of a hardware variation or other factors related to the ‘sample’, the 
SNR may vary from one time to another. The source of this hardware difference will be 
addressed in the discussion; however the goal here is to demonstrate that the differences 
in SNR were not responsible for observed changes in metabolite levels. In an attempt to 
make the SNR consistent throughout the study, the time point where SNR is determined 
to be best, we added extra noise into the raw data in the time domain using software 
coded using Matlab7 (Matlab, The Mathworks, Natick, MA). Noise was only added to 
the data collected at a particular time period, at which time the SNR of water and the 
metabolites were significantly higher than those collected at other time points within the 
study period. The time period with a reduced noise, and hence elevated SNR, was 
identified by the correlation analysis between SNR and magnet age. Discrete pseudo-
random noise (3008 data points) was produced in the time domain. The noise amplitude 
was estimated from the mean noise level - the standard deviation of the last 32 complex 
points.  The random noise amplitudes were added to each real and imaginary point 
utilizing the phase information obtained from the water reference of each dataset. Pre-
processing, spectral fitting and quantification described in our previous study3,4 were 
repeated for the simulated spectra (with extra noise). In order to reduce a bias, all 
procedures described in this section were repeated in triplicate. Quantified metabolite 
levels were averaged across the three trials.  
 
4.2.4 Statistical analyses 
Statistical analyses were completed using statistical software PASW Statistics version 
18.0.0 for Windows. Correlation analyses were performed versus magnet age for the 
SNR, linewidth and noise level after the addition of extra noise with the Pearson product 
moment coefficient (P = 0.001).  As indicated above, this was performed at each 
measurement period in each group, including all of the samples in the patient group, and 
including all of the samples in the control group.  
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Quantified NAA and tGL levels were then compared using the same statistical method 
described in our previous study.4 Correlation analyses were also conducted with respect 
to the subject age instead of magnet age at each measurement period. This is to identify 
whether there are changes within the group due to patient age.  
 
4.2.5  SNR simulation: precision in the metabolite quantification 
In this study, random noise was added to datasets in the time domain data for the time 
point that was identified to have a higher SNR (lower noise) than the remaining data sets 
in the study duration. The origin of this difference will be discussed later. In order to 
understand how the noise level of the data affects the fitting of the metabolites, one 
characteristic spectrum was selected from the entire study set. This dataset was fit to 
determine the metabolite levels as described above. The ideal noiseless fit was taken as 
an ideal spectrum and 149 different noise sets were added to this spectrum in the time 
domain using the same approach described in the “random noise” section of this study. 
Pre-processing, spectral fitting and quantification were repeated for the simulated spectra. 
These quantified spectra were sorted by NAA SNR, chosen to be between 1.34 and 8.49, 
as this is the SNR range observed the original 80 months study (as determined below). 
Groups (n = 11) were created based on NAA SNR (group averages: 1.75, 2.19, 2.84. 3.25, 
3.71, 4.22. 4.77. 5.34. 5.81, 6.25 and 7.13).  Quantified metabolite peak areas were 
averaged in each group.  
 
4.3 Results 
4.3.1 Correlation with respect to magnet age (across 
measurement periods) 
In the original data sets, NAA SNR decreased with magnet age in the anterior cingulate 
(r = -0.460, P = 0.002, N=44) and the thalamus (r = -0.460, P  = 0.001, N=45) in 
schizophrenia (i.e. combining NT, 10 months and 80 months). The correlation of NAA 
SNR versus magnet age in the thalamus is presented in the top-left of Figure 4-1(a).   
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Figure 4-1: NAA signal-to-noise ratio in the left thalamus in schizophrenia versus 
magnet age.  
Plot at the top-left (a) is a correlation across the measurement periods (n = 45). The 
rest of the plots are the correlations at each measurement period; NT (b), 10 months 
(c) and 80 months (d). 
 
Thalamic tGL SNR in the schizophrenia group also demonstrated a trend to decrease over 
magnet age (r = -0.423, p = 0.004).  There was no significant correlation between noise 
levels in the water suppressed data and magnet age in the anterior cingulate (r = 0.379, 
P = 0.012) and the thalamus (r = 0.372, P = 0.012) in schizophrenia patients. Figure 4-2 
represents the change in the metabolite noise in the left thalamus with respect to the 
magnet age in schizophrenia. None of the variables in the control group (Con1 plus 
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Con2) was significantly correlated with the magnet age in both the anterior cingulate and 
the thalamus.  
 
Figure 4-2: Metabolite noise in the left thalamus in schizophrenia versus magnet 
age. 
Noise is calculated from the last 32 complex points in the time domain. Plot at the 
top-left (a) is a correlation across all data samples (n = 45). The rest of the plots are 
the correlations at each measurement period; NT (b), 10 months (c) and 80 months 
(d). 
 
In these plots, there is an apparent trend toward lower noise levels during the first two 
years of the study (Figure 4-2).  This might explain some elevated SNR, for example the 
water SNR, observed during that time period.  This was particularly curious because of 
the gradient coils upgrade occurring at that specific time. One possible culprit is a change 
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in the digital filter that occurred at that time.  Because of these hardware upgrades, a 
possible transition time was defined at 2 years in magnet age. The noise manipulation 
described in “random noise” in the method section was performed in the data collected 
only in the first 2 years since August 27, 1997, the oldest data set in this data analysis. 
Because of the timing of the measurements, extra noise was added to the six data sets at 
NT and 10 months assessment in the schizophrenia group and four data sets at Con1 in 
the control group.  
 
4.3.2 Metabolites SNR vs. magnet age (at the individual 
measurement periods) 
Correlations with respect to the magnet age at each measurement period are summarized 
in Table 4-1. In the left anterior cingulate, tGL SNR was significantly decreased over 
magnet age at 10 months assessment in schizophrenia (r = -0.809, P = 0.001), and there 
was a trend toward a decrease at NT (r = -0.741, P = 0.002). There was a trend toward 
decreasing NAA SNR at NT (r = -0.714, P = 0.003) and 10 months assessment (r = -0.750, 
P = 0.005) in schizophrenia. Metabolite noise was significantly increased at 10 months in 
schizophrenia (r = -0.828, P = 0.001). None of the other correlations were significant in 
either schizophrenia or controls in the anterior cingulate.  
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Table 4-1: Pearson product-moment coefficients with respect to the magnet age 
before and after adding extra noise into the first 2 years data. 
(a) 
NT 10 mo 80 mo All 
N=15 N=14 N=16 N=44 Anterior 
Cingualte 
Original With 
noise Original 
With 
noise Original Original 
With 
noise 
Water linewidth Ns ns ns ns ns ns ns 
Water SNR Ns ns ns ns ns ns ns 
Water noise Ns ns ns ns ns ns ns 
Metabolite noise Ns ns 0.828** ns ns ns ns 
NAA SNR -0.714* ns -0.750* ns ns -0.460* ns 
tGL SNR -0.741* ns -0.809** -0.747* ns ns ns 
NAA level Ns ns ns ns ns ns ns 
tGL level Ns ns ns ns ns ns ns 
(b) 
NT 10 mo 80 mo All 
N=16 N=12 N=17 N=45 Thalamus 
Original With 
noise Original 
With 
noise Original Original 
With 
noise 
Water linewidth Ns ns ns ns ns ns ns 
Water SNR Ns ns -0.810** ns ns ns 0.426* 
Water noise Ns ns ns ns ns ns ns 
Metabolite noise 0.682* ns 0.755** ns ns ns ns 
NAA SNR -0.689* ns -0.765* ns ns -0.460** ns 
tGL SNR Ns ns -0.806** ns ns -0.423* ns 
NAA level Ns ns ns ns ns ns ns 
tGL level Ns ns ns ns ns ns ns 
 
Significant r-values in schizophrenia in the (a) anterior cingulate and (b) thalamus are 
shown in this table (**P < 0.001, *P < 0.005). R-values in the original 80 months study 
(before adding noise) are presented in the left column (Original) in each NT, 10mo and 
All group section as well as 80 mo column. Statistical values after the noise manipulation 
are presented in the right column (With noise) with italic font in each section except 80 
mo column. Extra noise were added in the data sets, collected in the first 2 years (six data 
sets of each NT and 10 mo). 
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In the left thalamus, water SNR at 10 months assessment in schizophrenia was 
significantly decreased over magnet age (r = -0.810, P = 0.001). There is a trend toward a 
negative correlation with magnet age for NAA SNR at NT (r = -0.699, P = 0.003) and 10 
months (r = -0.765, P = 0.004) and tGL SNR at the 10 months assessment (r = -0.806, 
P = 0.002). Figure 4-1 (b, c, d) presents the correlations between NAA SNR in the 
thalamus and magnet age. There is a trend for metabolite noise to increase over magnet 
age at both NT (r = 0.682, P = 0.004) and 10 months (r = 0.755, P = 0.005)  (Figure 4-2). 
No significant correlation was found in controls in the thalamus.  
Correlations after the noise manipulation were presented in the right column in NT and 
10 months in Table 4-1. Extra noise was added to the data collected in the first 2 years 
and replaced with the original data sets. This noise simulation was not performed in the 
data in the 80 months group because these data were collected beyond the transition time 
(i.e. first 2 years in the magnet age). An observed trend toward decreasing tGL SNR over 
magnet age persisted in the anterior cingulate after adding noise (r = -0.747, P = 0.002). 
No other significant correlation was observed after the noise simulation in any other 
variables, measurement periods, regions and groups.  
 
4.3.3 Metabolite levels after adding random noise 
Mean metabolite levels in the original 80 months study and in these data with extra noise 
are presented in Figure 4-3 (anterior cingulate) and 4-4 (thalamus). There was a trend 
toward decreasing NAA level from 10 months to 80 months assessment in the left 
anterior cingulate in the original data (P = 0.031 > 0.025) but no significance was 
observed in the same data after adding the random noise (P = 0.114). There was no other 
significant difference between the original and simulated data in the left anterior 
cingulate. Thalamic NAA level at 80 months was significantly decreased from 10 months 
in the original data (P = 0.013) (Figure 4-4). After adding the noise, this was no longer 
significant (P = 0.029 > 0.025) but there was a trend toward a decreasing level. The tGL 
level at 80 months was significantly decreased from NT in schizophrenia in the original 
data (P = 0.044) and the data with extra noise (P = 0.024). 
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Figure 4-3: Metabolite levels in the anterior cingulated before and after data 
manipulation. 
Anterior cingulate NAA (a) and tGL (b) concentration levels in the 80 months study 
(Original data) and the same data with adding random noise (With extra noise). 
Error bar indicates the group standard deviation in each measurement period. 
Extra noise were added into 6 data sets in each NT (n = 15) and 10mo measurement 
(n = 14), as well as 4 data sets in Con1 (n = 17).   
Measurement period: NT, never-treated; 10mo, 10 months assessment; 80mo, 80 
months assessment; Con1, control at scan #1; Con2, control at scan #2. Metabolites: 
NAA, N-acetylaspartate; tGL, sum of glutamate and glutamine. 
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Figure 4-4: Metabolite levels in the thalamus before and after the data 
manipulation. 
Thalamic NAA (a) and tGL (b) concentration levels in the 80 months study 
(Original data) and the same data with adding random noise (With extra noise). 
Error bar indicates the group standard deviation in each measurement period. 
Extra noise were added into 6 data sets in each NT (n = 16) and 10mo measurement 
(n = 12), as well as 4 data sets in Con1 (n = 17). **P < 0.025, *P < 0.050.  
Measurement period: NT, never-treated; 10mo, 10 months assessment; 80mo, 80 
months assessment; Con1, control at scan #1; Con2, control at scan #2. Metabolites: 
NAA, N-acetylaspartate; tGL, sum of glutamate and glutamine. 
 
4.3.4 SNR simulation: precision in the metabolite quantification 
In this study, noise was added to some time points, and the potential impact on metabolite 
levels was investigated. It is therefore important to know whether and to what extent 
modifying the noise level will alter the fitting of the metabolites. Figure 4-5 represents 
the variation of 7 quantified metabolite levels with respect to NAA SNR. In this study, 
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the addition of noise for the first 2 years of an 80 month study caused the NAA SNR in 
the time domain to decrease by approximately 25% (from 4.818 to 3.612).  The grand 
mean was calculated from the data in the first 2 years of the study, including both groups 
(schizophrenia & control) and both regions (anterior cingulate & thalamus).  These 
average SNR before (dashed line) and after adding the noise (solid gray line) are shown 
as vertical lines in Figure 4-5. The average NAA SNR drop in the anterior cingulate and 
the thalamus was 25.5% and 24.7%, respectively.  Figure 4-6 represents the changes in 
quantified NAA metabolite level with respect to the simulated NAA SNR. Error bars 
represent the group standard deviation of the NAA level in each SNR group. The 
Coefficient of Variation (CV) around the mean NAA SNR before and after adding noise 
is approximately 10.6% and 11.9%, respectively.  The CV for the glutamate level 
degrades from 13.3% to 21.1%, and similarly for the glutamine level, from 25.2% to 
36.0%.  Figure 4-7, 8 and 9 represent the quantified glutamate, glutamine and tGL levels 
with respect to the NAA SNR, respectively.  
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Figure 4-5: SNR simulation.  
Quantified metabolite levels with respect to the NAA signal-to-noise ratio in the time 
domain. 149 spectra were simulated with using a noise-free spectrum. These spectra 
are sorted into 11 different NAA SNR. Two vertical lines show the average NAA 
SNR before (dashed line) and after (solid gray line) adding the extra noise in the 
first 2 years data in 80 months study. The averages are taken among the first 2 years 
data, including 6 data sets of each NT and 10 months as well as 4 data sets in Con1 
in both anterior cingulate and thalamus.  
Cho, choline; Gln, glutamine;  Glu, glutamate; Myo, myo-inositole; NAA, N-
acetylaspartate; tCr, total creatine; tGL, total glutamatergic metabolite (Glu+Gln). 
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Figure 4-6: SNR simulation, NAA level.  
Quantified NAA levels with respect to the NAA SNR. Error bar indicates the 
standard deviation in each group sorted by NAA SNR. Two vertical lines show the 
average NAA SNR before (dashed line) and after (solid gray line) adding the extra 
noise in the first 2 years data in 80 months study. The averages are taken among the 
first 2 years data, including 6 data sets of each NT and 10 months as well as 4 data 
sets in Con1 in both anterior cingulate and thalamus. 
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Figure 4-7: SNR simulation, glutamate level.  
Quantified glutamate levels with respect to the NAA SNR. Error bar indicates the 
standard deviation in each group sorted by NAA SNR. Two vertical lines show the 
average NAA SNR before (dashed line) and after (solid gray line) adding the extra 
noise in the first 2 years data in 80 months study. The averages are taken among the 
first 2 years data, including 6 data sets of each NT and 10 months as well as 4 data 
sets in Con1 in both anterior cingulate and thalamus. 
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Figure 4-8: SNR simulation, glutamine level.  
Quantified glutamine levels with respect to the NAA SNR. Error bar indicates the 
standard deviation in each group sorted by NAA SNR. Two vertical lines show the 
average NAA SNR before (dashed line) and after (solid gray line) adding the extra 
noise in the first 2 years data in 80 months study. The averages are taken among the 
first 2 years data, including 6 data sets of each NT and 10 months as well as 4 data 
sets in Con1 in both anterior cingulate and thalamus. 
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Figure 4-9: SNR simulation, tGL level.  
Quantified total glutamatergic metabolites (tGL) with respect to the NAA SNR. 
Error bar indicates the standard deviation in each group sorted by NAA SNR. Two 
vertical lines show the average NAA SNR before (dashed line) and after (solid gray 
line) adding the extra noise in the first 2 years data in 80 months study. The 
averages are taken among the first 2 years data, including 6 data sets of each NT 
and 10 months as well as 4 data sets in Con1 in both anterior cingulate and 
thalamus. tGL: total glutamatergic metabolites (glutamate + glutamine) 
 
4.3.5 NAA SNR vs. subject age 
No significant correlation with respect to the subject age was found either in the anterior 
cingulate or the thalamus at any measurement periods, including all measurement periods 
in both groups. The top plot in Figure 4-10 shows the correlations between NAA SNR 
and the subject age in schizophrenia. The bottom plot in Figure 4-10 represents the same 
correlation following the addition of the pseudo-random noise.  Figure 4-11 presents the 
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thalamic NAA SNR with respect to the subject age in controls. The original data is shown 
in the top plot while the bottom panel shows the data with the extra noise.  
 
Figure 4-10: Correlations between subject age and thalamic NAA signal-to-noise 
ratio in schizophrenia 
 NAA signal-to-noise ratio at all measurement periods (N = 45) were involved in this 
correlation analysis. Top plot (a) indicates the original 80 months study. Bottom plot 
(b) indicates the data after the noise simulation, applied to the 12 data sets (6 of each 
NT and 10 months) collected in the first 2 years 
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Figure 4-11: Correlations between subject age and thalamic NAA signal-to-noise 
ratio in controls 
NAA signal-to-noise ratio at all measurement periods (N = 33) are involved in this 
correlation analysis. Top plot (a) indicates the original 80 months study. Bottom plot 
(b) indicates the data after the noise simulation, applied to the 4 data sets in Con 1 
group collected in the first 2 years. Con 1, initial scan for the controls; Con 2, 
follow-up scan for the same controls. 
 
97 
 
4.4 Discussion 
4.4.1 Correlations in SNRs with magnet age 
Metabolite SNRs in both the anterior cingulate and the thalamus in schizophrenia were 
significantly or demonstrated a trend to be decreased over magnet age while there was no 
correlation in those SNRs in the control group. These decreases in SNRs may be a result 
of or enhanced by the hardware changes. Several hardware components in our MR 
system were upgraded or replaced in the first two years. This partially explains why no 
significant correlation against magnet age was found in controls, who were scanned much 
later than schizophrenia patients. In addition, only four control scans were performed in 
the first two years while twelve scans (six scans in each NT and 10 months) were 
completed in the schizophrenia group.  
Despite the significant drop in metabolite SNRs, no SNR change was confirmed in the 
routine QA, which was performed by a system manager every week. Quality control in 
our 4T MR system was conducted by taking a magnitude image with the echo planar 
imaging (EPI) sequence using an identical phantom each week. It is possible that SNRs 
measured by a spectroscopy sequence are more sensitive compared to SNRs determined 
using an imaging sequence. Indeed, water SNR in this study was not significantly 
correlated with the entire magnet age in any regions or groups.  
Another possible explanation is the digital filter. In our protocol, the digital filter was 
manually turned on during the MRS acquisition to reduce the noise in the first two years 
of the study. At this point in time, the hardware upgrade removed the need for the digital 
filter, and the operating protocol was adjusted as such. Therefore, metabolite SNRs in the 
first two years might be higher than SNRs in the remaining years. Water SNRs were not 
as high as metabolite SNRs in the first two years. This suggests noise reduction by the 
digital filter might be insufficient to improve the water SNR because water signal was too 
high to be affected by the noise reduction. Since metabolite SNRs were influenced by the 
hardware replacement and/or the digital filter, we were concerned whether the observed 
differences in metabolite levels in our 80 months study4 could be attributed to this 
artifact. It will be discussed in the next section whether the differences in metabolite 
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levels observed in the 80 months study are affected by the changes in SNRs caused by the 
addition of the random noise. 
 
4.4.2 Metabolite concentration levels: influence of random noise 
Thalamic tGL level was still significantly decreased at 80 months from NT in 
schizophrenia patients even though some of the data sets in NT were replaced with the 
manipulated data. The differences were more significant (P = 0.024) compared to the 
original data sets (P = 0.044). Thalamic NAA level in schizophrenia, however, only 
showed a trend toward decreasing from 10 months to 80 months after the data 
manipulation (P = 0.029) while significant decrease was observed before adding extra 
noise (P = 0.013). The significance in the anterior cingulate NAA level (P = 0.031) 
worsened after extra noise was added (P = 0.114). This data is artificial in the sense that 
noise has been added in the first two years of data to make the SNR comparable across 
the study duration. However this still demonstrates that a hardware modification such as 
this may be responsible for a trend or a significant finding in the data that is not 
physiological in nature. Thus particularly in a long-term study, significantly different 
SNRs may skew statistical comparisons.  
The influence of the noise is inconsistent between NAA and tGL levels. This most likely 
originates because the NAA level is due to a single metabolite while tGL level is 
composed of two different metabolites. tGL level was found to be higher than the NAA 
level, and the standard deviation of the tGL level is lower than that of NAA. Therefore, 
tGL is more stable than NAA in terms of the quantified metabolite level in the 
spectroscopic study. A possible explanation for the differential improvement in the 
significance in the thalamus and anterior cingulate would be the metabolite SNR in the 
original in-vivo data. Overall, SNR measured in the anterior cingulate spectra is lower 
than those in the thalamus spectra. Lower SNR in the anterior cingulate is caused by the 
decreased sensitivity due to the sinus cavity.  Lower SNR spectrum often leads to misfit 
and inconsistent spectral fitting compared to the higher SNR spectra. Therefore, spectra 
in the anterior cingulate are vulnerable to increasing noise level compared with the 
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spectra in the thalamus. The effect of the SNR changes on metabolite quantification will 
be discussed with an SNR simulation in the next section.  
 
4.4.3 SNR simulation: SNR and precision of the metabolite 
quantification 
Metabolite quantification is sensitive to the SNR. In this SNR simulation, all quantified 
metabolite levels vary within the actual range of the NAA SNR in the 80 months study 
(Figure 4-5). The standard deviation of quantified metabolite levels are observed to 
worsen as the SNR of NAA decreases. In particular, glutamate and glutamine levels show 
a large standard deviation at NAA SNR less than 3 (Figure 4-7 and 4-8). Insufficient 
SNR leads to inconsistent quantification because fitting of the lower SNR spectra is 
dependent on the noise signal at the data collection.  
At the higher NAA SNR, group standard deviations are more consistent compared to 
those at lower SNR but metabolite levels still vary. This simulation suggests that it is 
very important to maintain the SNR at a constant level, especially in longitudinal studies. 
Significant SNR changes between or within subjects may lead to errors in statistical 
comparisons. 
One key finding of these simulations is that noise level may impact the fitting of the 
metabolite spectra.  In fact, Figure 4-5 suggests that changing the SNR to below 3 would 
result in a very different fit of the metabolites.  However over the change in SNR in this 
study, Figures 4-5 to 4-9 suggest that a significant change in the metabolite level is not 
expected.  Thus the change in noise level of this simulation is not expected to impact the 
fit of the metabolite level.   
 
4.4.4 Limitations 
Either metabolite levels or SNRs were not corrected for subject age. Neuronal 
metabolites such as NAA are expected to decrease as the subjects age.6 High metabolite 
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SNR at the first two years might be influenced by subject age as the data were collected 
at an earlier age compared to their 80 months assessment. However, since there is no 
correlation between metabolite SNR and subject age (Figure 4-10 and 4-11), an age effect 
for the metabolite SNR is less likely in this study.  
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Chapter 5  
5 Thesis summary 
5.1 Results summary and implications 
This thesis presents the results of a long-term study of schizophrenia, which is an 
extension of a previous longitudinal study.1 In the initial study, it was reported that the 
initially elevated glutamine level in schizophrenia patients decreased over the 30 month 
assessment period. Chapter 2 of this thesis presents a longitudinal study to investigate 
whether or not these findings persist out to 80 months in the same population. The 
driving hypothesis of this study was as follows: 
 
Hypothesis 1:  Significantly higher glutamatergic metabolites during the first episode will 
decrease in schizophrenia over the 80 months. Glutamatergic metabolite decreases will 
correlate with widespread gray matter losses and social functioning at a 7 year follow-
up. 
In Chapter 2, we found that glutamatergic metabolites and NAA levels as well as gray 
matter volume were significantly decreased in schizophrenia over 80 months. Reductions 
in those metabolite levels were significantly correlated with gray matter loss in the 
regions associated with schizophrenic symptoms. These results suggest that physiological 
and structural deterioration persist in schizophrenia for at least 7 years. Significant 
correlations suggest that an excitotoxic process may lead to a neuronal dysfunction, 
which is eventually observable as widespread gray matter loss.  
Loss of glutamatergic metabolite levels were inversely correlated with the Life Skills 
Profile (LSP) rating scale, a standardized social functioning, in schizophrenia at 80 
months assessment. Glutamatergic reduction over 80 months was larger in a patient with 
lower LSP score, which indicates impaired social functioning. This negative correlation 
suggests that glutamatergic metabolite levels may reflect deteriorating social functioning 
in schizophrenia.  
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These results confirm our first hypothesis that glutamatergic metabolites and gray matter 
decreased over time. The loss of metabolite was significantly correlated with the gray 
matter losses, and social functioning was negatively correlated with the loss of 
glutamatergic metabolite levels. This long-term study demonstrates evidence of 
neurodegenerative processes in schizophrenia correlating metabolite levels with the 
physiological and structural changes, as well as social functioning. This is the first study 
to demonstrate these findings. 
However coincident reductions in neuronal metabolite levels and gray matter volume 
raise a further question. Is it possible that structural changes in the brain resulting in 
change in gray matter volume are affecting metabolite levels such as glutamatergic 
metabolites and NAA? The purpose of Chapter 3 of this thesis was therefore to probe 
whether or not changes in the gray matter in the spectroscopy voxel could be responsible 
for observed changes in metabolite levels. To answer this question, the following 
hypothesis was derived: 
 
Hypothesis 2: Loss of glutamatergic metabolites in first episode patients over time will be 
related to gray matter loss in the voxel of interest but will not be significantly affected by 
signal-to-noise changes associated with gray matter loss. NAA levels will be less likely to 
be affected by gray matter loss in the voxel of interest or signal-to-noise changes.  
In Chapter 3, we examined whether decreased metabolite levels were significantly 
associated with the loss of gray matter in the long-term study (Chapter 2). Comparing the 
metabolite levels adjusted by the gray matter in the voxel of interest, significance in NAA 
levels hovered around the threshold while significance in the glutamatergic metabolite 
levels turned out to be non-significant. This suggests that gray matter in the spectroscopy 
voxel may not be responsible for the NAA levels but possibly for the glutamatergic 
metabolite levels. This therefore suggests that significantly decreased glutamatergic 
metabolite levels in the long-term study may be explained through the loss of neuropil, 
which is observed as gray matter loss. The subtle association between gray matter and 
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NAA level may be partially explained by the connection between 1H MRS measured 
NAA levels and neuronal integrity.  
Significances in metabolite signal-to-noise ratio were unchanged by the gray matter 
adjustment. Despite the significant loss of gray matter in the voxel of interest, the 
influence of the gray matter on the metabolite signal-to-noise ratios was likely minimal. It 
suggests that signal-to-noise ratio defined in this study is more affected by the hardware 
performance and the data acquisition than the anatomical structure and location in the 
head.  
These results confirm the hypothesis that gray matter may be associated with the 
glutamatergic metabolite levels but not with the NAA levels. This line of inquiry led to a 
significant amount of discussion surrounding hardware performance, and factors that may 
impact the signal-to-noise ratio. It is important for example that the metabolite levels and 
gray matter volumes were measured under the same experimental condition in the MR 
system. That way observed differences were due to biological changes and not a result of 
the hardware. This is an even more important consideration when undertaking a long 
term study such as ours that spanned 7 years.   
It was noted from our long term study that due to a hardware modification, there was a 
change in the noise level of the system. Hardware replacements and/or upgrades are 
inevitable, particularly as the duration of a study becomes longer. Although our MR 
technician carefully maintained the MR system, with rigorous quality control, this change 
in the system noise may have affected the metabolite signal-to-noise ratio in our study. It 
then became crucial to understand whether or not the signal-to-noise ratio changed due to 
this hardware modification, and if so, whether or not the metabolite quantification was 
affected. In Chapter 4, a series of data manipulations and simulations were presented to 
answer these questions. It was hypothesized that: 
 
Hypothesis 3: Significant differences in brain metabolites observed in our long-term 
study would persist after data manipulation to simulate a constant signal-to-noise ratio 
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throughout this study. Thus, Signal-to-noise ratio changes during our long-term study 
were not a major issue if the changes are modest. 
 
Chapter 4 demonstrated the influence of signal-to-noise ratio on the metabolite 
quantification. Data manipulation, adding extra noise into the corresponding data, in the 
long-term study (Chapter 2) showed that the impact of signal-to-noise ratio is different 
for each of the individual metabolites. Significance in the NAA levels reported in the 
long-term study turned out to be a trend while the significance in tGL levels was 
improved after the data manipulation. This implies a risk in long term studies that an 
errant or inconsistent signal-to-noise ratio may skew the statistical significance of the 
quantified metabolite levels.  
A signal-to-noise simulation was conducted to examine how metabolite signal-to-noise 
ratios affect the quantified metabolite levels. Differing amounts of noise were added into 
a noise-free spectrum generated from a data set in the long-term study. Lower signal-to-
noise leads to an increased standard deviation in each metabolite level in groups of 
measurements having similar signal-to-noise ratios in this study. Quantification precision 
is decreased in those spectra with lower signal-to-noise. This simulation showed a 
potential risk that larger distributions of signal-to-noise ratio within a subject group may 
lead to difficulties in observing statistically significant differences or changes.  
Thus these results confirm hypothesis 3, that these simulations in Chapter 4 demonstrate 
that significance in metabolite levels in the long-term study (Chapter 2) persisted with the 
addition of extra noise. Metabolite signal-to-noise ratios in the long-term study were 
maintained within a reasonable range, holding a similar precision in the metabolite 
quantification throughout the study. A broad range of signal-to-noise ratios however may 
lead to inconsistent metabolite quantification and a distorted statistical significance. This 
is crucial when differences or changes are reported using the statistical significance. To 
our knowledge, this is the first study to examine the role of hardware and signal-to-noise 
over long periods of time in this type of clinical study. 
105 
 
 
In summary, this thesis demonstrated the following using in vivo 1H MRS: (1) evidence 
that glutamatergic and NAA metabolite levels decline in schizophrenia for at least 7 
years, (2) decreases in glutamatergic metabolite levels are associated with widespread 
gray matter losses and decreases in social functioning in schizophrenic patients, (3) 
decreases in glutamatergic metabolites may be accounted for at least in part by a loss of 
neuropil within the voxel of interest although an earlier degenerative process resulting in 
both the loss of neuropil and decreased glutamatergic metabolites cannot be ruled out, 
and (4) although hardware changes over time can influence signal-to-noise, differences in 
metabolite level persisted demonstrating that it is possible to carry out a long-term MRS 
study in a clinical population.   
These findings have a number of implications for the understanding of the 
pathophysiology of schizophrenia as well as the feasibility of long-term MRS studies of 
clinical disorders. On the whole, findings would be consistent with degeneration related 
to glutamatergic excitotoxicity.2 However, they do not rule out an early 
neurodevelopmental lesion related to genetic or environmental factors which might have 
been uncovered by cortical pruning which occurs during adolescence. The findings could 
also be accounted for in part by a genetically programmed loss of neuropil caused by a 
loss of nerve growth or other factors but the finding of increased glutamatergic 
metabolites without a change in gray matter in the first assessment would not be 
consistent with this explanation. If a loss of nerve growth factors caused the loss of gray 
matter, loss of gray matter would be expected at the first assessment. The effect of 
medication cannot be ruled out as well but it appears unlikely as there were few 
differences in gray matter and no differences in glutamatergic metabolites between the 
initial assessment before medication and the follow-up 10 months later on medication. It 
is possible that chronic medication effects may have influenced metabolite levels and 
gray matter but there appeared to be few significant correlations between the dose of 
medication and gray matter loss and no significant correlation between the dose of 
medication and metabolite levels. 
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Findings in the present studies are consistent with a parallel series of 31P MRS studies 
which demonstrated increased membrane breakdown products in first episode 
schizophrenic patients in regions associated with increased glutamatergic metabolites.3 A 
follow-up of these patients showed diminished membrane breakdown products over time 
in these regions in keeping with the loss of glutamatergic metabolites.4 An increase in 
membrane breakdown products was also demonstrated in a subsequent study5 in regions 
showing later loss of gray matter suggesting that a degenerative process may precede the 
loss of gray matter. The findings of this thesis combined with the 31P MRS studies 
implicates glutamate as a possible target of therapeutic intervention in this disorder. 
Current treatments do not prevent social deterioration. The association between the loss 
of glutamatergic metabolites and social functioning in this study suggests that it might be 
possible to arrest this process with pharmaceuticals that target glutamate.  
One recommendation arising from this study would be that researchers engaged in long 
term spectroscopy studies not only track the daily quality assurance using the SNR of a 
uniform phantom, but also that the metabolite signal and noise be monitored on a regular 
basis, in particular, before and after major hardware upgrades.  In this way the potential 
risk of hardware signal/noise changes impacting the metabolite quantification can be 
mitigated.  
 
5.2 Future work 
This thesis is composed of data acquired at 4 Tesla, which provided a good separation 
between glutamate and glutamine spectra. As described in Chapter 2 and 3, glutamine 
levels measured with 1H MRS are better indicators for the glutamate neurotransmission, 
which might cause an excitotoxicity in schizophrenia. In Chapter 2, these two metabolite 
levels were quantified separately. Using a higher magnetic field strength such as 7 Tesla 
would be the logical next step to improve the spectral resolution. Improved signal-to-
noise ratio is expected at 7 Tesla compared to at 4 Tesla as the signal-to-noise ratio is 
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proportional to the magnetic field strength. High signal-to-noise ratios may improve a 
measurement of low concentration metabolites in the human brain such as GABA, which 
is synthesized from glutamate with an enzyme glutamic acid decarboxylase.  
High signal-to-noise ratio also supports better spectral fitting and the precision of the 
metabolite quantification. Using a phased array coil also improves the signal-to-noise 
ratio when compared to a head coil. 32 channel phased array coils are available. Using a 
phased array coil at 7 Tesla, our laboratory conducts functional magnetic resonance 
spectroscopy (fMRS), which allows the measurement of dynamic metabolite changes 
from a functionally activated area determined by fMRI.  It would be interesting for 
example whether external stimuli might impact observed metabolite changes, helping to 
understand the disease mechanism, or perhaps hinting at other approaches to disease 
management. We are also utilizing two dimensional chemical shift imaging, which 
measures the metabolite levels within the entire slice. Two dimensional CSI will enable 
the evaluation of metabolite changes simultaneously over a wider area.  Perhaps 
metabolite changes in one region may reflect similar changes in other regions of the brain 
not presently under consideration, further enhancing our understanding of the disease 
mechanism.  
Updating a priori knowledge is necessary to improve the spectral fitting. If a metabolite 
or macromolecule component is missing in the a priori information, the fitting algorithm 
attempts to compensate the missing peak with the existing components, resulting in a 
quantification error. An automated fitting procedure minimizes a user-dependent factors 
such as setting the seeding values, which are required to run the Fitman program and are 
manually chosen in each spectrum. The Fitman program uses the Levenberg-Marquardt 
minimization algorithm that seeks the global minima, the best compromise between raw 
data and fitting. If the seeding value is not properly set, the fitting algorithm may find the 
local minima and not the best fit global minimum.  
Some difficulties associated with longitudinal studies were discussed in Chapter 4. A 
longitudinal study is a powerful way to investigate progressive disorders such as 
schizophrenia and Alzheimer’s disease. The longer the follow-up period is, however, the 
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more likely hardware upgrades or replacements are required. Thus, the signal-to-noise 
ratio might be different before and after the hardware changes. We demonstrated that a 
wide range of signal-to-noise ratio might distort the metabolite quantification and 
statistical comparison in Chapter 4. Measuring the water signal-to-noise ratio in vivo as 
well as the regular quality control with a phantom would help to maintain the quality of 
the spectra in a longitudinal study.  
To maintain a reasonable range for the signal-to-noise ratio, the same head coil could be 
utilized with similar MR systems. If the signal-to-noise ratio was significantly elevated 
due to a hardware upgrade during a project, a possible solution to maintain a certain 
signal-to-noise ratio would be to transfer the head coil to another MR system, in which a 
similar signal-to-noise ratio is expected.   
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Appendices 
Appendix A: No differences in metabolite levels in mood 
disorder patients compared to healthy volunteers 
Nery et al.1 reported no statistical differences in the metabolite levels between 37 
unmedicated participants with major depressive disorder (MDD) and 40 matched healthy 
controls. They measured the metabolites N-acetyl aspartate (NAA), glutamate (Glu), 
phosphocreatine plus creatine (PCr + Cr), choline-containing compounds (GPC + PC), 
myo-inositol (Myo) and Glu plus glutamine (Glu + Gln) in a 2.0 × 2.0 × 2.0 cm voxel in 
the left dorsolateral prefrontal cortex  using in-vivo proton magnetic resonance 
spectroscopy (1H MRS) at 1.5 T. Nery et al.1 also found that NAA levels negatively 
correlated to the length of illness in MDD patients (r = -0.460, P = 0.003) and they found 
gender differences in PCr + Cr concentrations. 
Our group measured metabolite levels in a 1.5 × 1.0 × 1.0 cm voxel in the left anterior 
cingulate using 1H MRS at 4 Tesla.2 In contrast to Nery et al.,1 our methods allowed the 
measurement of Glu and Gln separately. The data shown in Figure A-1, was taken from 6 
depressed patients with psychotic symptoms and 3 likely bipolar patients with a mixed 
state with psychotic symptoms. Sixteen first episode schizophrenia patients and 16 
controls matched to the schizophrenic group on which we have previously reported were 
included for comparison.2 All patients were drug naïve. Three of 16 data sets from 
schizophrenia patients were excluded. These 3 spectra were unusable because of the 
subjects involuntary movements and/or excessive breathing during the scan. 
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Figure A-1: Metabolite levels in schizophrenia, control, and mood disorder. 
Metabolite levels measured by proton magnetic resonance spectroscopy from 1.5cm3 
in the left anterior cingulate. Error bar represents the group standard deviation. a, 
SZ vs. DEP (unpaired two-tailed t-test, t = 2.084, P = 0.055); b, CONT vs. SZ 
(t = 2.373, P = 0.025); c, SZ vs. DEP (t = 2.267, P = 0.041); d, group effect in 
multivariate test (F = 3.619, P = 0.037).  
Group: CONT, normal control; DEP, depressed patients with psychotic symptoms; 
SZ, schizophrenia. Metabolites: Cho, choline; Gln, glutamine; Glu, glutamate; Myo, 
myo-inositol; NAA, N-acetylaspartate; tCr, total creatine. 
 
The three-group univariate F, 2/35, corresponding to these differences in Gln levels was 
3.619 (P = 0.037). LSD post-hoc test was performed in each pair of the groups (two-
tailed, α = 0.05). 1H MRS metabolite levels in 9 mood disordered patients before 
treatment were not significantly different from controls. Although the sample was small, 
our result and those of the MDD study1 suggest there may be no significant differences in 
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1H MRS metabolites in frontal areas between depressed patients and healthy controls. 
However, there may be differences between depressed patients with psychotic symptoms 
and schizophrenic patients. We observed  significantly decreased Gln levels (t = 2.494, 
P = 0.019, d.f.  = 1,35) and a trend toward elevated Glu (t = 1.914, P = 0.068, d.f.  = 1,35) in 
mood disordered compared to schizophrenic patients in the left anterior cingulate. 
Moreover, Gln levels in schizophrenia patients were significantly lower than controls 
(t = 2.150, P = 0.040, d.f.  = 1,35). These results suggest that the mechanisms of mood 
disorders and schizophrenia are different in spite of some overlap in clinical symptoms.   
Glutamatergic metabolites have been found to be generally decreased in depressed 
patients compared to controls and increased compared to controls in studies of bipolar 
patients.3,4 Nery et al.1 point to a number of reasons for differences between studies 
including sample characteristics, acquisition and post-processing parameters. The Nery et 
al. study1 also points out the need for publication of negative findings which are too often 
not reported.  We observed that mood disordered patients differ from schizophrenia, but 
not from controls.   If the comparison had only been made between mood disordered 
patients and controls, then this negative result may not have been reported.  This 
illustrates the need for comparative psychiatric groups to parse out findings related to 
psychosis from those unique to MDD.  
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Appendix B: Description of imaging, spectroscopy, pre-
processing, fitting and quantification 
Data were acquired with a 4.0 Tesla Varian (Palo Alto, California, USA)/Siemens 
(Erlangen, Germany) whole body scanner with a Varian Unity Inova console, located at 
the Centre for Functional and Metabolic Mapping of the Robarts Research Institute, 
London, Ontario, Canada. A circularly polarized transmit and receive head coil was used. 
Global shimming was manually performed with linear and 2nd order shim coils and 
followed by T1-weighted transverse anatomical images (three-dimensional magnetization 
prepared fast low angle shot (MP-FLASH) sequence, repetition time (TR) = 11 ms, echo 
time (TE) = 6.4 ms, inversion time (TI) = 500 ms, flip angle = 30 degrees, 64 slices, matrix 
256 × 256, 0.78 × 0.78 mm resolution, field of view = 20 cm, slice thickness = 2.75 mm). 
Using those T1-weighted images, the 10 × 15 × 10 mm (right-left, anterior-posterior, 
inferior-superior direction) 1H spectroscopy volumes were positioned at the left anterior 
cingulate gyrus (Brodmann Area (BA) 32) and the left thalamus.  
Magnetic resonance spectroscopy data were obtained with a single voxel stimulated echo 
acquisition mode (STEAM) sequence (TE = 20 ms, mixing time (TM) = 30 ms, 
TR = 2000 ms, dwell time = 500 µs, 8 step phase-cycling). The power of the 90-degree 
radio frequency pulses and the CHESS water suppression pulses were optimized for each 
voxel. After local shimming, water suppressed data (256 averages) followed by water 
unsuppressed data (16 averages) were collected. Data post processing included zero order 
eddy current correction (ECC) and line shape correction with the QUECC technique.1 
The remnant water resonances in the water suppressed spectra were subtracted with the 
Hankel-Lanczos singular value decomposition algorithm.2 Water suppressed spectra were 
fit through an in-house software Fitman program2,3 to the first 1024 data points (512 ms) 
in the time domain using a priori knowledge. Our model is based on in vitro 
measurements from twelve metabolites plus literature values for eleven macromolecules 
added to the a priori knowledge.4,5 Metabolite concentration levels were quantified with 
equations6 that included the ratio to water concentration in each spectroscopy voxel. The 
voxel water concentration depends on the voxel fraction of gray matter, white matter, and 
114 
 
CSF along with the water content of each of these tissues. The measured water signal was 
therefore corrected by the voxel’s fractional tissue content and assumed literature values 
for the water content of each tissue type (gray matter 81%, white matter 71%, CSF 
100%). Fractional tissue content was measured from semi-automated segmentation of the 
voxel location within the 3D T1-weighted image set as in our previous study.6  
Quality of each MR spectrum was evaluated with using Visual Appreciation Scale (from 
1 to 5) as well as Baseline and Artefact Scale (from A to E), introduced by Théberge et 
al.6 We excluded the spectra in which the gamma-glutamate peak (2.35 ppm) was not 
identified and/or severe hashing was seen in a part of the spectra (i.e. rating lower than 
5B). Only metabolites with a group coefficient of variation (group CV = (group standard 
deviation / group mean) × 100%) less than 75% are reported. Group CV less than 75% in 
the normally distributed samples means that 10% of the samples have a chance to be 
negative values, which never emerge in our fitting procedure. This criterion protects the 
statistical analysis from the metabolites which reach the lower detection threshold. We 
elected not to use a criteria based on percent Cramér–Rao lower bound (CRLB) since 
CRLB are only a portion of the total inter-individual variability of the data. It is the total 
inter-individual variability (group standard deviation) that determines the final ability to 
distinguish between two groups (a.k.a, SDD = smallest detectable difference). Metabolites 
survived from the criterion are NAA, glutamate (Glu), glutamine (Gln), choline (Cho), 
total creatine (tCr), myo-inositol (Myo) in the anterior cingulate and the thalamus, taurine 
(Tau) and scyllo-inositol (Syl) in the thalamus only. The “total glutamatergic 
metabolites” (tGL) refers to a sum of Glu and Gln levels measured individually. It should 
be noted that tGL is different from Glx, which is commonly used in the spectroscopy 
literature. Glx has an investigator-dependent definition which can refer to a variety of 
quantities. Often, it refers to the integrated spectral area encompassing the peaks from the 
3C and 4C multiplets of Glu, Gln, GABA (gamma-aminobutyric acid), the aspartyl 
moiety of NAA and NAAG, the glutamate moiety of NAAG as well as signals from 
macromolecules. The concept of Glx was useful in the context of overlapping peaks at 
lower field strengths (1.5 T) and was used by many of the earlier studies where separate 
quantification of these metabolites may have been more difficult. 
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Appendix C: Sample spectra 
 
Figure C-1: Fitted in vivo MR spectra 
 Fitted spectra with 2Hz line broadening collected from the left thalamus in a 
schizophrenia patient at NT (a) and at 80 month assessment (b). Preprocessed 
spectrum (gray line) with fit (solid line) on the top, corresponding metabolite 
components in the middle, and the residual shown below.  The boxed regions 
indicated in (a) and (b) are magnified in (c) and (d) showing the glutamate (dotted 
line) and glutamine (solid line) components. 
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